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vAbstract
The Human Immunodeficiency Virus (HIV) is able to infect CD4+ T cells as well as
macrophages. Macrophage-tropism has been linked to determinants in the envelope of
HIV. These determinants allow envelopes to exploit low levels of CD4 for infection.
Macrophages are an important reservoir of virus, especially during chronic infection, and
are likely responsible for the bulk of virus produced after CD4+ T cells have declined.
Viral factors that may impact the ability to infect macrophages are worth studying
because this cell type is so important in infection.
It was previously reported that the macrophage-tropic primary isolate AD8 was
vpu-independent. The molecular clone YU-2, derived from brain tissue without culture,
was also reported to be macrophage-tropic despite having a mutation in the vpu start
codon. It was therefore possible that vpu-independent envelopes could evolve in vivo. To
examine this possibility, I constructed chimeras containing wild type or defective vpu
start codons, and gp160 sequences from AD8, YU-2 or SF162 (a vpu-dependent control).
I also used full length AD8 and YU-2 with wild type or defective vpu start codons. I
infected macrophages with equal amounts of virus, and measured viral output over two
weeks. Viruses with defective vpu start codons were released to lower levels compared to
their wild type vpu counterparts. In contrast to previous reports, the AD8 envelope is not
vpu-independent for replication in macrophages. The YU-2 envelope is also not vpu-
independent.
Macrophage-tropic envelopes from late stages of infection can be sensitive to
antibodies that bind the CD4 binding site on gp120, implying that macrophage-tropic
vi
envelopes have more exposed CD4 binding sites. Neutralizing antibodies may act as
modulators of macrophage-tropism over the course of infection. Using chimeras
containing gp120 sequences derived from the PBMC of four HIV+ patients, I examined
the capacity for envelopes to infect macrophages. Three patients (MM1, 4, and 8) had
macrophage-tropic envelopes before and after developing autologous neutralizing
antibodies. Three patients (MM1, 4, and 23) developed heterologous antibodies against
IIIB, an easily neutralized T-cell line adapted strain of HIV-1. This data indicates that
macrophage-tropism in these patients is not modulated by the presence of neutralizing
antibodies.
The macrophage-tropism of envelopes tends to segregate depending on the tissue
origin of the virus. Envelopes from two separate tissues from the same patient exhibit
very different infectivity characteristics. The B33 envelope, from brain tissue, is very
infectious and is macrophage-tropic, while the LN40 envelope, from lymph node tissue,
is weakly infectious and is not macrophage-tropic. Replacing the entire gp41 of LN40
with that of B33 restores some infectivity to LN40. The cytoplasmic domain of gp41
contains many motifs important for assembly and infectivity. To examine which motifs
are responsible for the weak infectivity of LN40, I made chimeras of gp41, as well as
point mutations in gp41. The LN40 chimera containing the entire gp41 of B33 restored
the most infectivity. Point mutations in the palmitoylation site, Pr55gag binding region,
and dileucine motif at the C-terminus also restored infectivity when combined.
Determinants in the gp41 cytoplasmic domain are responsible for the weak infectivity of
vii
LN40; however, it is possible that there are contributing determinants in gp120, such as
the ability to use low levels of CD4.
Here, I examined how changes in the vpu and env genes of HIV-1 can impact
infectivity, especially infectivity of macrophages. Changes that adversely impact the
virus’ ability to infect macrophages may also impact the overall course of disease.
However, the data here show that retaining the ability to infect, and replicate in,
macrophages give HIV an advantage. I speculate that retaining the ability to infect
macrophages gives the virus a reservoir for later in disease, when CD4+ T cells have been
depleted, as well as way of avoiding neutralizing antibodies. This work further defines
the importance of macrophages in HIV-1 infectivity and disease.
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Preface
Data in Chapter III originally appeared in “Effects of vpu start codon mutations on
replication in macrophages”, KH Richards and PR Clapham, Journal of General
Virology, 2007 Oct;88(Pt 10):2780-92.
Data in Chapter IV on construction of HXBc2/ patient chimeras and neautralization
assays originally appeared in “Development of the antibody response in acute HIV-1
infection”. M. Aasa-Champan et al, AIDS, 2004 Feb 20;18(3):371-81. Used with
permission.
1Chapter I: An Introduction to AIDS and HIV
A Short History of HIV and AIDS
In 1981, a US physician reported several cases of homosexual men with
immunological dysfunction [112]. These patients’ illnesses were characterized by CD4+
T cell decline, opportunistic infections and rare cancers. This collection of symptoms was
named Acquired Immune Deficiency Syndrome (AIDS).
In 1983, Barré-Sinoussi et al. reported the isolation of a new human retrovirus
from patients diagnosed with AIDS [17]. This virus was eventually named Human
Immunodeficiency Virus (HIV). Two types of HIV have been discovered: HIV-1 and
HIV-2. HIV-2 was first reported in 1986 in West African subjects [50].
An estimated 25 million people worldwide have died of AIDS since the beginning
of the epidemic 25 years ago. In 2007, 2.5 million people were newly infected with HIV.
The majority of people living with HIV is in sub-Saharan Africa; however numbers are
rising in Asia and North America. Worldwide, 33.2 million people are currently living
with HIV [258][209][271].
Phylogeny, Origins and Epidemiology of HIV
HIV belongs to the Retroviridae family, genus lentivirus [16]. The retroviridae
family is characterized by the ability to convert the viral genomic single-stranded RNA to
double stranded DNA via the enzyme reverse transcriptase. Lentiviruses typically cause
slow disease progression and primarily target lymphocytes and macrophages [244].
2HIV-1 and HIV-2 have distinct genomic differences, discussed in more detail
below. Simian Immunodeficiency virus (SIV) was discovered in primates, but usually
does not cause AIDS-like illness in their natural hosts [64].
HIV-1 is divided into 3 groups: Main (M), Outlier (O), and Non-M, Non-O (N).
The M group is divided further into 9 subtypes: A, B, C, D, F, G, H, J, and K [181][62].
The M group also contains a number of circulating recombinant forms (CRFs), which
appear to be recombinants of the 9 subtypes [167].
HIV-1 and HIV-2 likely arose from separate zoonosis events. HIV-2 is genetically
closely related to SIV from sooty mangabey monkeys (SIVsmm) [124][103]. HIV-1 groups
M and N are genetically related to SIV from chimpanzees (SIVcpz) [102][56]. SIVcpz
seems to be a combination of SIV from greater spot-nosed monkeys (SIVgsn) and SIV
from red-capped mangabeys (SIVrcm) [11]. Group O viruses are genetically related to SIV
from gorillas (SIVgor) [261].
Subtype A viruses are prevalent in Africa, and can be found in North Africa, the
Middle East, Eastern Europe, Central and South Asia. Subtype B viruses are prevalent in
North America, the Caribbean, South America, Western Europe and Australia. Subtype B
can also be found in Eastern Europe and Asia. Subtype C viruses are prevalent in South
Asia, and can be found in Africa. Over half of all new infections worldwide have been
identified as subtype C. CRFs can be found in North Africa and the Middle East (CRF
AG), East Asia (CRF BC), and South Asia (CRF AE). Most CRFs can also be found in
Africa. Subtypes D, F, G, H, J, and K can also be found in Africa, along with viruses
belonging to groups O, and N [136].
3Genome Organization
HIV-1, HIV-2, and SIV are complex retroviruses. Their genomes encode the
prototypical gag, pol, and env genes, along with several other genes [271][209][120].
These additional genes are vif, vpr, rev, tat, and nef [119][52]. HIV-1 also contains the
vpu gene [53][247]. HIV-2 and SIV contain the vpx gene [137]. gag, pol, and env are
structural genes; they are translated into polyproteins that must be cleaved by either viral
or cellular proteases before maturation.
The remaining proteins are translated from spliced mRNAs. Tat, rev, and nef are
the first genes transcribed and expressed during viral replication, followed by vif, vpu,
vpr, env, gag, and gag-pol.  Tat and rev are regulatory genes; vif, vpr, vpu, and nef are
accessory genes [119][84].
The entire viral genome is flanked by Long Terminal Repeats, or LTRs. These areas
are not translated, but contain many cis-acting elements that help direct production of
viral proteins. These elements include the transactivation response region (TAR) stem,
the Poly A site, the primer binding sequences (pbs) stem, and the core encapsidation
signal (Ψ). These elements regulate the elongation of viral RNA, splicing, RNA
dimerization, packaging and reverse transcription of the viral genome
[19][179][180][212][28][108][259]. The topography of the HIV-2 LTRs is different from
that of HIV-1 [177][98][157].
Schematics of the genome organizations of HIV-1 and HIV-2 are in Fig. 1.1
4Fig. 1.1 Schematics of the genome organizations of HIV-1 and HIV-2.
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5 The HIV-1 Life Cycle
Productive infection of cells by HIV-1 occurs in a stepwise process [84]. This
process is outlined below, and in Fig. 1.2.
Step 1: Viral entry into target cell via CD4 and a coreceptor (either CCR5 or
CXCR4). Viral and plasma membranes fuse.
Step 2: Partial uncoating of the virus capsid, and reverse transcription of the viral
genome.
Step 3: Transport of the pre-integration complex (PIC) to the nucleus.
Step 4: Integration of the viral DNA into the host cell chromosomal DNA.
Step 5: Transcription of the viral genome into mRNA; viral mRNA transported to
the cytoplasm.
Step 6: Envelope synthesized in the endoplasmic reticulum; gag and gag-pol
synthesized in the cytoplasm.
Step 7: Viral proteins transported to cell’s plasma membrane.
Step 8: Condensation of gag, gag-pol, and viral genomic RNA at the cell
membrane (surface in most cell types; however, in macrophages, this step may
occur at late endosomal membranes).
Step 9: Virus particles released from cell membrane.
Step 10: Processing of gag to create mature virus particles.
Steps that are important to this thesis will be discussed in more detail in the
appropriate sections.
6Fig. 1.2 The HIV-1 life cycle. Numbers above correspond to steps described in the text.
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7Pathogenesis and Tropism of HIV-1
HIV can be transmitted in three ways: 1) sexual contact with an infected individual,
2) contact with the blood of an infected individual through a wound (open cuts,
intravenous needle use), and 3) vertically transmitted from infected mother to child
(during childbirth or breastfeeding). Once inside the body, HIV-1 infects CD4+ T helper
cells, macrophages, and some populations of dendritic cells [292][222]. Dendritic cells in
mucosal membranes can carry HIV to the lymph nodes, where the virus can be passed to
circulating T cells [106][151]. Immune cells in the gut-associated lymphoid tissue
(GALT) are rapidly depleted in the first weeks of infection [35][265][33]. A gradual
decline in the numbers of CD4+ cells in the periphery is seen over the course of disease.
HIV infection in the gut results in leakage of bacterial products into the blood,
contributing to general activation of the immune system [34]. Chronic activation of the
immune system provides activated CD4+ T-cells as targets for HIV, which leads to
activation induced cell death (AICD) [49][10]. These situations likely cause the decline
of CD4+ cells seen over the course of infection. Death from AIDS, or a variety of
opportunistic infections, usually occurs 10 years post infection, unless antiretroviral
treatment is used (see the section Treatment of HIV).
Many infected individuals also develop HIV Associated Dementia (HAD) late in
disease. The mechanisms of HIV entry into the central nervous system are unclear,
although evidence points to infected monocytes crossing the blood-brain barrier as being
the culprits [47][110][162][240].
Upon acute infection with HIV-1, there is a spike in viral replication, which then
levels out for a number of years before increasing again later in disease [74]. HIV-
8specific antibodies can be detected 4-8 weeks after infection (Fig 1.3) [1][200][205].
Once these antibodies are detected, the individual is considered seroconverted.
As was mentioned above, HIV infects cells using CD4 (a member of the
immunoglobulin superfamily) present on T-cells and macrophages as its main receptor
[144][182][63]. HIV also requires a coreceptor to gain entry to cells. HIV uses either
CCR5, or CXCR4 as the coreceptor [48][71][73][90]. Isolates that are only able to use
CCR5 are called R5-tropic; isolates that use only CXCR4 are called X4-tropic. Isolates
able to use both CCR5 and CXCR4 are called dual-tropic, or R5X4, viruses. Most HIVs
are R5-tropic, with up to 50% switching to X4-tropic during late infection. The switch
from R5-tropism to X4-tropism is associated with accelerated progression to AIDS and
death [54][253]. Scarlatti et al. followed children with progressive HIV-1 infection.
Viruses isolated from the asymptomatic stages of infection generally were R5-tropic;
viruses isolated from the symptomatic stages were X4-tropic. Children in which the
switch to X4-tropism occurred early had poor prognoses [220].
In cell culture, some viral isolates are CD4-independent, meaning that they do not
need to use CD4 to enter cells; they are able to use only a coreceptor. The in vivo
significance of this observation is unclear, as these CD4-independent viruses tend to also
be sensitive to neutralizing antibodies [153][126][148][82].
Macrophages are important for the establishment, persistence, and pathogenesis of
HIV infection. Macrophages infected with HIV-1 are resistant to cytopathic effects,
allowing them to become important reservoirs of virus [266]. Macrophages in the
submucosal tissues may be the initial targets for HIV-1, allowing for dissemination of
9virus throughout the immune system [266]. Perivascular macrophages are a likely
reservoir of HIV-1 in the brain, leading to infection of microglia of monocyte/
macrophage lineage [91] [109] [251] [281] [57]. Infected macrophages may also play a
role in viral escape from antiretroviral therapy.
Because macrophages express low levels of CD4 and CCR5, a virus must be able to
utilize low levels of these receptors in order to infect. Primary X4-tropic viruses tend to
infect macrophages less efficiently compared to R5-tropic viruses [72]. Non-macrophage-
tropic R5 viruses are prevalent in immune tissue and blood, while R5 macrophage-tropic
viruses are readily found in brain tissue, especially in HIV+ patients with dementia
[203][111]. R5 viruses from late stages of disease have been reported to be more
macrophage-tropic [113][162][257].
In vivo, HIV-1 targets activated T-cells, as well as resting/non-dividing T-cells.
During the acute phase of infection, HIV-1 mainly targets activated T-cells, which
provides the bulk of HIV-1 particles [292]. During the chronic phase, resting T-cells and
macrophages are responsible for the persistence of the virus in the immune system, acting
as viral reservoirs [49]. They are also responsible for dissemination to the central nervous
system and the GI tract [47][110][162][240][135][195].
10
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Fig. 1.3 Course of HIV infection. Acute infection is characterized by a drop, then rise, in CD4+ T-cells, and
a spike in viral load over several weeks. Chronic infection is characterized by a slow decline of CD4+ T-
cells, and a slow increase in viral load over several years.
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Plasma viral load
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cell count
HIV+
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The Genes of HIV-1
As mentioned above, HIV-1 is a complex retrovirus. Its 9 genes are classified into
three types: 1) structural genes, 2) regulatory genes, and 3) accessory genes. Structural
genes encode proteins that are responsible for structural elements of the virus particle.
These genes include env, gag, and pol. Regulatory genes are responsible for regulating
viral gene expression. These genes include tat and rev. Accessory genes were once
considered non-essential for viral replication in cell culture. However, some of these
genes have been found to be important in cultures of some cell types, as well as in vivo.
The accessory genes are nef, vif, vpu, and vpr.
These genes are summarized in Table 1.1. The env and vpu genes will be discussed
in greater detail in sections The Envelope of HIV-1 and The Vpu Gene and Protein of
HIV-1, respectively.
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Table 1.1 The Genes of HIV-1
Gene Protein
Characteristics
Primary Functions Location in the
virus particle
References
Tat Nuclear protein Increases the steady-
state levels of viral
RNA by forming a
more processive RNA
pol II transcription
complex
Not applicable [65] [92] [294] [61]
Rev Nucleolar
phosphoprotein
containing a
nuclear
localization signal
(NLS)
Exports HIV mRNAs
out of the nucleus into
the cytoplasm for
translation; does this
by binding Rev
Response Element
(RRE) on viral pre-
mRNAs.
Not applicable [18] [89] [171] [172]
[173]
Nef Membrane-
associated
phosphoprotein
Downregulation of
surface molecules
CD4, MHC-I, MHC-
II, CD3 T-cell
receptor complex,
CD28; enhancement
of virus infectivity,
modulation of cellular
activation pathways
Within capsid [20] [67] [104] [115]
[143] [231] [223]
[249] [250]
Vif Protein containing
many domains for
interacting with
cellular proteins;
forms
homodimers
Interacts with
APOBEC3G (restricts
viral replication by
converting cytosines
to uracils during
reverse transcription);
sends APOBEC3G to
the ubiquitin-
proteosome pathway
for degradation
Not applicable [55] [118] [155] [170]
[174] [176] [183]
[235] [236] [289]
[291]
Vpu Membrane-
associated protein
Downregulated CD4
from the ER,
enhances virus release
Not applicable [229] [279]
See The Vpu Protein of
HIV-1
Vpr Small protein Stimulate LTR-driven
gene expression,
promote transport of
PIC to nucleus, arrest
infected cells in G2,
induce apoptosis,
modulate mutation
rates during reverse
transcription
Within capsid [52] [290] [12] [94]
[121] [142] [168]
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Table 1.1 con’t The Genes of HIV-1
Env Glycoprotein; initially
synthesized as a polyprotein
gp160
Interaction with
CD4 and
CCR5/CXCR4 to
gain entry into
target cells
In surface
plasma
membrane, as
trimer spikes
[6] [295] [276]
See The
Envelope of HIV-
1
Gag Initially synthesized as a
polyprotein Pr55Gag; cleaved by
viral protease (PR) during
budding from the cell surface
into matrix (MA), capsid (CA),
nucleocapsid (NC) and p6.
Structural protein
MA: targets
Pr55Gag to cell
membranes
CA: forms
protective core
around viral
genomic RNA;
promotes virus
assembly
NC: encapsidates
viral genomic
RNA into virions
p6: recruits
Tsg101 to promote
virus release
MA: just
inside viral
lipid bilayer
CA: center of
virus particle,
cone around
viral genomic
RNA
NC:
complexed
with viral
genomic
RNA
p6: location
unknown
[7] [8] [97]
[101] [105]
[123] [130]
[160] [178]
[189] [196]
[197] [214]
[215] [268]
[282]
Gag-pol Initially synthesized as a
polyprotein Pr160Gag-Pol;
autocatalyzes itself to free
protease (PR); PR then cleaves
the remaining polyprotein into
reverse transcriptase (RT) and
integrase (IN)
Structural protein
PR: viral protease
RT: converts viral
genomic RNA into
DNA upon
uncoating in the
cytoplasm
IN: integrates viral
DNA into the host
cell genomic DNA
PR: between
MA and CA
RT and IN:
within capsid
[13] [37] [60]
[100] [138]
[270]
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The Envelope of HIV-1
The env gene encodes the envelope polyprotein gp160. gp160 is cleaved into two
proteins, gp120 and gp41, by cellular furin/ furin-like proteases [116]. gp120 is heavily
glycosylated, and is found on the surface of virus particles [81] [159] [295]. gp41 is
inserted in the virus plasma membrane via a transmembrane domain, and has a
cytoplasmic domain with many motifs responsible for envelope assembly and
trafficking [75] [76] [267] [221]. gp120 and gp41 are non-covalently linked on the
virus particle surface and arranged in trimers [122] [80]. These trimers are called
envelope spikes.
gp120 has two domains, an inner domain and an outer domain [152][283]. In the
CD4-bound form, the outer domain is connected to the inner domain by a 4-stranded
antiparallel β-sheet called the bridging sheet (see Fig.1.4a). Areas called the variable (V)
loops are also present. There are 5 variable loops in gp120, designated V1 to V5 [243].
The stems of the V1/V2 loops make up part of the bridging sheet (Fig. 1.4a) [152] [285].
The CD4 binding domain residues line the cavity between the inner and outer
domains [152]. The bridging sheet and the V3 loop, located on the outer domain, are
responsible for binding the coreceptor (either CCR5 or CXCR4) [152] [285] [25] [242].
Keeping the CD4 binding site recessed protects many important sites from being
recognized by the immune system [125] [82]. The variable loops’ sequences can evolve
quickly, providing rapid escape from any neutralizing antibodies targeted to these
immunogenic regions.
Analysis of V3 loop sequences has shown that CXCR4-usage is associated with
increased basic residues, fewer N-linked glycosylation sites, and increased positively-
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charged residues [66] [93] [125] [208]. Studies have also shown that the V1/V2 loop is
involved in coreceptor tropism; however, the specific residues and/or motifs involved are
poorly defined [283]. Recently, Huang et al. reported that the transmembrane domain of
gp41 also has a role in coreceptor tropism [131].
The ectodomain of gp41 (the section of the protein immediately before the
transmembrane domain) contains 2 heptad repeats, HR1 and HR2. HR1 and HR2 are
coiled-coil domains. They pack together in antiparallel to create the 6-helix bundle
important for membrane fusion (Fig. 1.5b) [39] [42] [275]. Further discussion of
functional domains in gp41 is in Chapter V.
Fusion of the virus membrane and the target cell membrane occurs in a stepwise
process. First, gp120 binds CD4. This causes conformational changes to occur in gp120,
exposing residues in the bridging sheet responsible for coreceptor binding [248] [218]
[44]. Next, the coreceptor is bound by the bridging sheet and the V3 loop [152] [242].
Conformational changes then occur in gp41 that allow the fusion peptide in gp41 to insert
into the target cell membrane. Finally, the 6-helix bundle brings the viral and cell
membranes together, allowing them to fuse, and the viral core is released into the
cytoplasm of the cell (Fig. 1.6) [149] [96] [41] [221] [70] [76] [75].
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Fig. 1.4 Ribbon diagrams of gp120 and gp41. a) gp120 , b) gp41 ectodomain of SIV. Reproduced
from [152] and [39].
a) b)
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Fig. 1.5 Fusion of the HIV and host cell plasma membranes. Step 1: Virus particle approaches CD4+
coreceptor+ target cell. Step 2: gp120 interacts with CD4, causing conformational changes that expose the
coreceptor sites; gp120 then interacts with the coreceptor. Step 3: Conformational changes occur in gp41,
allowing the fusion peptide to insert into the target cell membrane. The 6-helix bundle forms, bringing the
viral and cell membranes together for fusion.
Step 1
CORECEPTOR
VIRUS PARTICLE
CELL SURFACE
CD4
gp120
gp41
Step 2
Step 3
6-helix bundle
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The Vpu Gene and Protein of HIV-1
The vpu gene is unique to HIV-1, and some SIVs [15] [58] [59]. vpu likely
originated in SIVcpz [11]. There is no equivalent gene in HIV-2. 80 nucleotides of the 3’
end of vpu overlap the 5’ end of env. vpu and env are transcribed together on a bicistronic
mRNA, and translation of vpu occurs via leaky scanning by ribosomes, while translation
of env occurs via discontinuous ribosome-scanning [232] [9]. Mutations that disrupt the
vpu reading frame result in increased translation of env [227] [245].
The vpu gene encodes a 16 kDa, 77-86 amino acid protein [53]. This protein has a
transmembrane domain at the amino-terminus, and two α-helices in the carboxy-terminus
in the cytoplasmic domain. These two domains have very distinct functions. The
transmembrane domain increases the release of virus particles from the plasma
membrane of the host cell [226]. The cytoplasmic domain degrades CD4 from the
endoplasmic reticulum [278].
The transmembrane domain can form ion channels similar to the HA of influenza
viruses [87] [229]. A single amino acid substitution in the transmembrane domain makes
vpu sensitive to the ion channel blocker rimantadine [128]. This domain also is able
overcome a cellular block present in HeLa cells and macrophages; but not present in
HOS and 293T cells [190] [263] [12] [69] [139] [228]. UBP is a cellular protein that
could possibly be indirectly involved in virus release. UBP binds to gag; vpu releases gag
from UBP, allowing gag to be moved to the cell surface for incorporation into virus
particles [40] [117].
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Vpu enhances virion release from plasma membranes by overcoming host cell
blocks. Several of these blocks have been identified. First, Hsu et al. found that vpu
destroys the host cell antiviral ion channel TASK-1 [129]. Second, Neil et al. and Van
Damme et al. reported that the cellular protein BST-2 (also known as tetherin) tethered
HIV-1 particles to the cell surface in the absence of vpu [191][260]. BST-2/ tetherin is a
membrane-associated protein with a cytoplasmic tail at the N-terminal, a transmembrane
domain, a predicted extracellular coiled-coil domain, and a GPI membrane anchor at the
C-terminal [191]. This protein is expressed in HeLa cells, which have a vpu-restrictive
phenotype, but is not expressed in 293T cells, which do not have a vpu-restrictive
phenotype. BST-2/tetherin is also expressed in terminally differentiated B cells, bone
marrow stromal cells, and plasmacytoid dendritic cells [260]. It is unclear whether this
protein is also expressed in macrophages.
Varthakavi et al. found that calcium modulating cyclophilin ligand (CAML) also
restricts virus release in the absence of vpu. This cellular block is overcome by vpu as
well as the envelope of HIV-2, and is likely the restrictive factor described in previous
work with heterokayrons. CAML is an integral membrane protein expressed in HeLa
cells, and is required for T cell survival; however, expression of this protein in
macrophages is unclear [262].
The CD4 degradation function of vpu is well understood. First, the α-helices of vpu
interact with the cytoplasmic tail of CD4 [30] [158] [269] [288]. Next, constitutively
phosphorylated  serines at positions 52 and 56 in vpu recruit cellular proteins β-TrCP,
skp1, and the E3 ubiquitin ligase complex [230] [22] [175].  Finally, CD4 is
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ubiquitinated, and retrotranslocated from the endoplasmic reticulum to the proteosome
[225] [99]. Removal of CD4 from the endoplasmic reticulum prevents the formation of
CD4-envelope complexes, allowing newly synthesized envelope to travel to the cell
surface for incorporation onto budding virus particles [141] [278].
Treatment of HIV
Over ten years ago, Highly Active Antiretroviral Therapy (HAART) was introduced
as a treatment option for people infected with HIV. Currently, five types of drugs are in
wide use in patients: RT inhibitors, PR inhibitors, IN inhibitors, fusion inhibitors, and
CCR5 antagonists. RT inhibitors are either nucleoside (NRTI) or non-nucleoside
(NNRTI) inhibitors. NRTIs are nucleotide mimics without the 3’-OH group (chain
terminators) [224]. They are incorporated into the growing DNA strand, preventing its
further extension. NNRTIs inhibit DNA polymerization by binding the active site in RT
[147]. PR inhibitors are generally synthetic compounds that are recognized by structure
by PR [184]. IN inhibitors inhibit strand transfer during integration of the viral genome
[88].
Fusion inhibitors interact with the HR1 domain after CD4 binding, preventing
formation of the 6-helix bundle. Enfuvirtide (also known as T20) has been used for many
years, especially as a salvage therapy [140] [154]. CCR5 antagonists block the
coreceptor, preventing gp120 from binding. One example of these CCR5 antagonists is
Maraviroc, which has been approved by the FDA for wide use [210] [280].
Unfortunately, viruses become resistant to these treatment options, and patients stop
responding to these therapies. Gag processing is also an attractive target because it must
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occur in a very specific order of steps. Currently, work in underway blocking the
maturation of CA [4] [161] [293]. Gag-processing drugs are still in the experimental
stages.
Since the HIV epidemic started over 25 years ago, the main goal has been to create
an effective vaccine. Vaccine strategies that aim to induce neutralizing antibodies have
been intensely studied. HIV-1 has many effective mechanisms for protecting itself from
these neutralizing antibodies. gp120 is heavily glycosylated, making it poorly
immunogenic. This glycosylation also protects the underlying amino acids from antibody
binding. Effective antibodies to the variable loops exist; however, the variable loops
frequently acquire sequence changes that help the virus evade the immune response.
Other immunogenic epitopes are present in HIV-1 (i.e., gp41, the CD4 binding site, and
the coreceptor binding sites), but these are typically hidden from antibodies [284] [38].
There are many obstacles to developing a vaccine for HIV. It is unlikely that there
will be an effective vaccine soon. The best hope for defeating the HIV/AIDS epidemic is
prevention and education.
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Chapter II: Materials and Methods
Patient Envelope Sources
Viral gp120 sequences were derived from the PBMC of four homosexual men
enrolled at St. Mary’s Hospital STD Clinic, London, UK [1]. Viral gp160 sequences were
derived from frozen brain and lymph node tissues from patients at autopsy at the
University of Edinburgh [201]. Viral gp120 and gp160 sequences were amplified by
PCR, as described previously [201] [1].
Construction of Molecular Clones
vpu+/- chimeras and full lengths
The molecular clone pNL4.3 was used to construct all chimeric viruses used in
the experiments described here. p3’SF162 (containing the 3’ half of the SF162 isolate
genome) was used to provide the vpu gene for all chimeras [46]. The construction of vpu-
p3’SF162 (ATG to ATA start codon mutation) was described previously [69]. Because
the vpu and env genes overlap, I constructed two sets of chimeric clones. One set of
clones was constructed to contain chimeric vpu genes and complete env genes; the second
set was constructed to contain chimeric env genes and complete vpu genes. Premature
stop codons were introduced into the nef genes of some of these latter constructs (Fig.
3.1).
The first set of chimeric clones was constructed using unique BbsI and BlpI sites
in p3’SF162. This allowed the introduction of different env genes into p3’SF162. Vpu
and env genes were then subcloned into pNL4.3 via the EcoRI and XhoI sites. Chimeric
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vpu+ and vpu- clones containing complete envelope genes from SF162, AD8 and YU-2
were constructed. This approach resulted in the NL4.3/AD8 and NL4.3/YU-2 chimeric
clones containing chimeric vpu sequences (69 amino acids from SF162, 28 amino acids
from AD8 or YU-2).
The second set of chimeric clones were constructed using the KpnI site
downstream of the vpu gene. These clones contain complete SF162 vpu genes, and
chimeric env genes. The leader sequences and first 12 amino acids of the env genes in
these clones were derived from SF162. Premature stop codons were introduced by PCR
mutagenesis of the nef gene at the XhoI site of the NL4.3/SF162, NL4.3/AD8 and
NL4.3/YU-2 chimeric clones described above.
Full-length AD8 with vpu+ or vpu- (ATA at the start codon) were described by
Theodore et al. [254]. Full length vpu- YU-2 (CTG at the start codon) was described by
Li et al. [163]. The YU-2 vpu start codon was repaired by PCR mutagenesis.
HXBc2 containing patient gp120 sequences
Patient gp120 sequences were amplified by Aasa-Chapman et al. using PCR from
PBMC as described previously [1]. With this PCR, BstEII and MluI sites were introduced
into the patient sequences at the beginning and end of gp120, respectively. These sites
were used to introduce the envelope sequences into the HXBc2 molecular clone.
B33 and LN40 chimeras and point mutations
B33 and LN40 gp160 sequences were amplified from patient tissues by PCR as
described previously [201]. Chimeras exchanging the entire gp41 were generated using
the MfeI site just upstream of the start of gp41, and the BlpI site downstream from
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envelope. Chimeras exchanging the C-terminal half of gp41 were generated using the
SalI site just upstream of the palmitoylation site, and BlpI. Point mutations were
generated by PCR mutagenesis.
Production of virus stocks
Virus stocks were prepared by calcium chloride transfection of HEK 293T cells
[203]. Vpu+/- chimeras and full length clones were co-transfected with a vector expressing
the vesicular stomatitis virus (VSV) G protein. HXBc2 chimeras containing either patient
gp120 sequences, or reference gp120 sequences were transfected alone. B33wt, LN40wt,
and variants of each were co-transfected with pNL4.3 env- to make pseudotype virus
stocks. pNL4.3 env- has a stop codon early in envelope, but expresses all other HIV
proteins, including Tat. All stocks were clarified by low speed centrifugation 48 hours
post-transfection, and were frozen at –152oC.
Cell Culture: Cell Lines and Primary Macrophages
HEK 293T [77], NP2 [241], TZM-bl and RC49 cells [207] were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) supplemented with 10%
heat-inactivated fetal calf serum (Sigma) and 10 µg/mL gentamicin (Invitrogen). Cells
were maintained at 37oC, 5% CO2.
Macrophages prepared by elutriation [234] [107] were provided by the University
of Massachusetts Medical School, Center for AIDS Research Cell Culture Core.
Macrophages were also prepared from PBMC by adherence [237] [238] [239]. Briefly,
PBMC were prepared from whole blood by Ficoll-Paque density gradient centrifugation.
5x106-5x107 PBMC were placed in 150cm3 Petri dishes in DMEM containing 10% heat
inactivated human plasma, and incubated at 370C for 3 hours. Plates were gently washed
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with DMEM three times, and DMEM, 10% human plasma was added. Plates were
incubated overnight, washed again the next day, then incubated for six days at 370C.
After six days, adherent macrophages were washed three times with EDTA, and gently
scraped off the plates with a cell scraper. Macrophages were resuspended to 2.5x105
cells/mL in DMEM, 10% human plasma, seeded in 48-well trays and incubated overnight
at 370C. Macrophages were infected the following day.
Infectivity Assays
NP2, TZM-bl, or RC49 cells were seeded in 48-well trays at 4x104/mL the day
before infection. The cells were infected with serial tenfold dilutions of virus for 3 hours
at 37oC. Virus was removed, fresh media was added and cells were incubated for 48
hours (in the case of TZM-bl cells) or 72 hours (in the cases of NP2 and RC49 cells).
Cells were fixed and stained in situ for lacZ expression (TZM-bl; see below for more
detail) or p24 antigen (NP2, RC49. and macrophages). After staining, cells were assessed
for focus-forming units (ffu) as described below.
To assess infection of macrophages by vpu+/- chimeras and full length clones,
macrophages in 48-well trays were infected with 100 µl viral stock, containing 25-50pg
reverse transcriptase (RT), of the VSV G pseudotyped viruses or other doses as
described. Macrophages were spinoculated by centrifugation at 1000 rpm for 45 minutes
[193]. After centrifugation, infected macrophages were incubated at 37oC for 3 hours.
Virus inoculum was removed, and cells were washed twice with fresh media.
Supernatants were harvested immediately following washing, then at approximately 3
day intervals for 2 weeks. Two weeks post-infection, the infected macrophages were
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fixed and stained for intracellular p24 antigen. Harvested supernatants were assessed for
RT activity by RT-ELISA (Cavidi Tech Inc. Sweden).
To assess infection of macrophages by HXBc2 chimeras, macrophages in 48-well
trays were infected with serial tenfold dilutions of virus. Macrophages were spinoculated
and incubated as described above. Virus inoculum was removed, fresh media was added,
and cells were incubated for one week. At the end of one week, macrophages were fixed
and stained for in situ p24. After staining, cells were assessed for ffu.
Single-round infectivity assay
I examined whether the AD8 envelope conferred a vpu-independent phenotype
when viral replication was limited to a single round. Macrophages were infected with
high doses of virus (1600 pg in 100 µl) by spinoculation as described above. After
incubation at 37oC for four hours cells were washed and, 10 µM of the reverse
transcriptase inhibitor, indinavir sulfate (NIH AIDS Research and Reference Program)
was added to cells to prevent subsequent rounds of replication. Supernatants were
harvested at 24, 48, 72 and 96 hours and infections were fixed after 96 hours. RT activity
of the supernatants was assessed by RT-ELISA.
In situ staining for lacZ expression in TZM-bl cells
TZM-bl cells carry the β-galactosidase gene controlled by an HIV LTR that is
expressed following infection and tat expression [272]. For viral titrations on these cells,
PBS containing 0.5 mg/mL X-Gal, 3 mM potassium ferricyanide, 3 mM ferrocyanide and
1 mM magnesium chloride was added directly to cells following fixation with 0.5%
gluteraldehyde in PBS at 4oC. Areas of infected HeLa TZM-BL cells were regarded as
28
foci of infection and were counted by light microscopy [203]. The titers (in ffu/mL) were
calculated.
In situ immunostaining for p24 antigen and envelope
Transfected 293T, infected NP2 cells, RC49 cells, or macrophages were fixed
with cold (-200C) 1:1 methanol: acetone, washed with PBS, then immunostained for p24
or envelope. For p24 staining, supernatants containing monoclonal antibodies 365 and
366 for p24 (UK Centre for AIDS Research) diluted 1:40 in 1% fetal calf serum, 0.05%
sodium azide in PBS were placed on cells, and incubated for 1 hour at room temperature.
For envelope staining, anti-gp41 Chessie 8 monoclonal antibody was used as described
for p24 staining. The cells were washed twice in 1% FBS, 0.05% sodium azide PBS.
Secondary antibody (goat anti-human conjugated to β-galactosidase) diluted 1:400 in 1%
FBS, 0.05% sodium azide PBS, was added, and incubated for 1 hour at room
temperature. Cells were washed once in 1% FBS, 0.05% sodium azide PBS, then twice in
PBS. PBS containing 0.5 mg/mL X-Gal, 3 mM potassium ferricyanide, 3 mM
ferrocyanide and 1 mM magnesium chloride (PBS-X-GAL) was then added to the cells.
Cells were incubated at 37oC for 3 hours. Infected cells stained blue. The titers (in
ffu/mL) were calculated.
Cell:cell fusion assays
HEK 293T cells transfected (described above) with env+ pSVIIIenv and pNL4.3
env- (at 4x105/mL) were cocultivated TZM-bl cells (seeded at 8x104/mL in 48-well trays
the day before). Syncytia formed 4-8 hours after mixing the two cell types. Cells were
fixed and stained with methanol containing 1% methylene blue and 0.25% basic fuchsin
for 10 minutes. Stained cells were then rinsed with PBS.
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Reverse Transcriptase (RT)-ELISAs
Virus stocks and supernatants from macrophage infections were assessed for
reverse transcriptase activity (RT) by RT-ELISA (Cavidi Tech Inc) as was described
previously [83]. Briefly, samples of inactivated virus were placed in wells containing a
solution containing bromo-deoxyuridine triphosphate and pre-coated with poly-A primer,
and incubated overnight at 33oC. Plates were washed the next day with buffer containing
0.75% Triton X-100, and 0.25% of the buffer solution provided with the kit. Tracer
solution (containing bromo-deoxyuridine triphosphate binding antibody conjugated to
alkaline phosphate) was placed in the wells, and incubated at 33oC for 90 minutes. Wells
were washed again, substrate was added, and wells were incubated at room temperature
for 30 minutes. Alkaline phosphatase activity was measured at 405 nm. The standard
curve was plotted, and the amount of RT in the samples was calculated (as pg/mL) using
the KC Junior program (BioTek Technologies).
gp120 ELISAs
High binding polystyrene (Costar) plates were coated with sheep anti-gp120
antibody (D7324; International Enzymes, Inc.) at 5 µg/mL in PBS, and incubated
overnight at 4oC. Plates were washed 2 times with PBS/ .05% Tween 20, then blocked
with PBS/ 3% BSA for 1 hour at room temperature. Plates were washed 4 times with
PBS/ .05% Tween 20. Samples and standard (HIV-1 LAVB recombinant gp120; Protein
Sciences Corporation) were serially diluted in PBS/ 1% BSA/ .02% Tween 20, and added
to wells. Plates were incubated at room temperature for 2 hours, then washed 10 times
with PBS/ .05% Tween 20. Anti-gp120 monoclonal antibody (b6; provided by D. Burton
at The Scripps Research Institute) was added to the wells at .4 µg/mL in PBS/ 1% BSA/
30
.02% Tween 20, and plates were incubated at room temperature for 2 hours. Plates were
washed 10 times with PBS/ .05% Tween 20. Goat anti-human IgG F(ab’)2 horseradish
peroxidase conjugated (31312; Pierce) diluted 1:5000 in PBS/ 1% BSA/ .02% Tween 20
was added to the wells, and plates were incubated at 37o C for 1 hour. Plates were washed
4 times with PBS/ .05% Tween 20, then once with water. Substrate (3,3´,5,5´-
tetramethylbenzidine, also known as TMB; Pierce) was added to wells, and plates were
incubated at room temperature for 30 minutes. Plates were read at 450 nm, standard
curves were plotted, and the amount of gp120 (in ng/mL) was calculated using the KC
Junior program (Bio-Tek Technologies).
Ultracentrifugation of virus particles
HEK 293T cells were transfected as described above. Forty-eight hours post
transfection, the supernatant was removed from the cells, and spun at 5000 rpm in a
Beckman-Coulter Ultracentrifuge (Optima L-90K, SW40 rotor). The supernatant was
filtered through a .45 µm or .22 µm syringe filter, layered onto a 20% sucrose cushion,
then spun at 22,000 rpm for 2 hours at 4oC in a Beckman-Coulter Ultracentrifuge
(Optima L-90K, SW40 rotor). The supernatant (including the sucrose) was poured off,
and the virus particles were resuspended in either Laemmli buffer for SDS-PAGE and
Western blotting, or DMEM for use in infectivity assays, RT ELISAs, gp120 ELISAs.
SDS-PAGE and Western blotting
Virus particles (isolated as described above) were resuspended in 2x Laemmli
buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, .004% bromphenol blue, .125 M
Tris HCl; Sigma), then loaded onto an 8% SDS-PAGE gel. Viral proteins were
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transferred to PVDF membranes, and probed for gp41 (with Chessie 8; NIH AIDS
Research and Reference Reagent Program) and p24 gag (with 183-H12-5C; NIH AIDS
Research and Reference Reagent Program). Bound antibodies were detected by
horseradish peroxidase chemiluminescence (Pierce).
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Chapter III: Effects of vpu start-codon mutations on HIV-
1 replication in macrophages: No evidence of rescue by
envelope
Introduction
The Human Immunodeficiency virus type 1 (HIV-1) vpu gene encodes a 77-86
amino acid,  ≈16 KDa protein [53]. Vpu is predominantly expressed in the endoplasmic
reticulum and the Golgi [198] [264], but also colocalizes with markers for recycling
endosomes [264]. The vpu protein contains a transmembrane domain at the amino
terminus and 2 cytoplasmic α-helices at the carboxyl terminus.
Over 80 nucleotides at the 3’ end of vpu overlap the 5’ end of env in the HIV-1
genome, and the two genes are transcribed together on a bicistronic mRNA [232].
Translation of the vpu protein occurs via leaky scanning by ribosomes, while the
translation of the env glycoprotein occurs via discontinuous scanning by ribosome [233]
[9]. Mutations that disrupt the vpu reading frame were reported to result in increased
translation of env [227] [245].
Vpu has two distinct functions during viral replication: 1) increased release of
virus particles from plasma membranes, and 2) degradation of intracellular CD4. The
transmembrane domain is responsible for virus release from host cell plasma membranes
[226] [229]. This domain forms oligomers that act as ion channels [87] [229].  A single
amino acid substitution in the TM domain was shown to render vpu activity sensitive to
the ion channel blocker rimantadine, causing a decrease in the release of virus particles
from infected cells [128]. Vpu was reported to interact with a host cell ion channel,
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TASK-1, which may have anti-viral activity disrupted by vpu [129]. Vpu has also been
reported to associate with a member of the tetratricopeptide family called Vpu Binding
Protein (UBP) [40]. UBP was shown to bind to vpu and p55 gag [40]. Overexpression of
UBP diminished the release of virus particles, suggesting that vpu may remove UBP from
gag in order to facilitate its transport to the cell surface [40] [117].
Vpu enhances virion release from plasma membranes by overcoming host cell
blocks. Several of these blocks have been identified. First, Hsu et al. found that vpu
destroys the host cell antiviral ion channel TASK-1 [129]. Second, Neil et al. and Van
Damme et al. reported that BST-2 (also known as tetherin) tethered HIV-1 particles to
the cell surface in the absence of vpu [191][260]. BST-2/ tetherin is a membrane
associated protein with a cytoplasmic tail at the N-terminal, a transmembrane domain, a
predicted extracellular coiled-coil domain, and a GPI membrane anchor at the C-terminal
[191]. This protein is expressed in HeLa cells, which have a vpu-restrictive phenotype,
but is not expressed in 293T cells, which do not have a vpu-restrictive phenotype. BST-
2/tetherin is also expressed in terminally differentiated B cells, bone marrow stromal
cells, and plasmacytoid dendritic cells [260]. It is unclear whether this protein is also
expressed in macrophages.
Varthakavi et al. found that calcium modulating cyclophilin ligand (CAML) also
restricts virus release in the absence of vpu. This cellular block is overcome by vpu and
the envelope of HIV-2, and is likely the restrictive factor described in previous work with
heterokayrons. CAML is an integral membrane protein expressed in HeLa cells, and is
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required for T cell survival; however, expression of this protein in macrophages is
unclear [262].
The cytoplasmic region of vpu downregulates CD4. This region recruits cellular
proteins that ubiquitinate CD4 and induce its degradation in a multi-step process. First,
the vpu α-helix interacts with the cytoplasmic tail of CD4 [29] [269] [288] [158].
Second, constitutively phosphorylated serines at residues 52 and 56  recruit the cellular
proteins β-TrCP, skp1, and the E3 ubiquitin ligase complex [230][22] [175]. Finally,
these proteins ubiquitinate CD4, triggering CD4 translocation from the endoplasmic
reticulum to the proteosome for degradation [225] [99] [225]. The removal of CD4 from
the secretory pathway by vpu limits the formation of CD4: envelope complexes in the
endoplasmic reticulum, allowing more efficient envelope trafficking through the
secretory system [279] [141]. The viral release function of vpu, rather than CD4
degradation, was shown to be more important for replication in macrophages, which
typically express low levels of CD4 [228] [156] [187] [14].
Like vpu, nef has been reported to downregulate CD4. However, while vpu removes
CD4 from the endoplasmic reticulum, nef downregulates CD4 from the plasma
membranes of infected cells via clathrin coated pits [204] [205] [114]. The requirement
of nef for HIV-1 replication in macrophages is controversial [36] [250].
HIV-2 and most SIVs lack a vpu gene, yet are fully functional in its absence.
Determinants in the HIV-2/SIV envelope have been reported to confer virus release [31]
[134]. In the HIV-2 envelope, these determinants have been proposed to be a GYXXθ
motif in the cytoplasmic tail, and an uncharacterized region in the ectodomain of gp41
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[2].  The GYXXθ region in the gp41 cytoplasmic tail has been shown to recruit adapter
protein 2 (AP-2) complex, and that this was required to maintain the enhanced virus
release function [192]. The determinants in SIV envelopes that may enhance virus release
have not been reported.
It is possible that HIV-1 envelopes may also evolve to overcome a lack of
functional vpu in a similar fashion to HIV-2/SIV envelopes, and that increased envelope
expression in the absence of vpu may provide an advantage in vivo. The envelope of the
AD8 isolate was reported to be vpu-independent because it conferred virus release from
transfected HeLa cells and replicated in macrophages in the absence of vpu [227].  YU-2,
which possesses a mutated vpu start codon, was cloned directly from the brain tissue of
an infected individual with neurological complications, [163]. YU-2 was reported to
infect macrophages efficiently, despite its vpu start codon mutation [163]. Mutations in
the vpu start codon also occur in about 1% of sequences derived from primary isolates in
the HIV databases. I hypothesized that vpu start codon mutations and the evolution of
vpu-independent envelopes to compensate may occur in vivo.
Here, I compared the capacity of AD8 and YU-2 envelopes that lack functional
vpu genes to replicate in macrophages. These results show that the elimination of vpu
function severely affected virion release and virus replication for both AD8 and
particularly for YU-2 in macrophages. Neither the AD8 nor YU-2 envelopes were able to
rescue macrophage replication for vpu-minus chimeric viruses. I also confirmed that
decreased virion release in vpu-defective infections of macrophages is due to a defect in
viral release exacerbated by inefficient viral spread.
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Results
Construction of vpu+/- chimeric viruses
Our lab previously described vpu+ and vpu- chimeras of SF162 and NL4.3 [69].
These constructs have complete vpu and env genes from SF162 in the background of
NL4.3. The vpu- construct contained a single mutation in the vpu start codon (ATG to
ATA mutation) that eliminated vpu function. I constructed additional chimeric viruses
carrying envelope sequences from HIV-1 AD8 and YU-2.  Two strategies were used to
prepare chimeras because the vpu and env genes overlap. The first set of chimeric clones
was constructed with full-length AD8 or YU-2 env genes and chimeric vpu genes. These
allowed us to evaluate the function of complete env genes, including the leader sequence,
in the absence of functional vpu.
The second set of chimeric clones was constructed with a complete SF162 vpu
gene and chimeric env genes. These viruses contain the env leader sequence from SF162,
which allowed us to test a potential role for this region in vpu-independence. This second
set of chimeric clones included some constructs that carried a premature stop codon in
nef, which enabled us to examine the possible effect of nef on virus release. Figure 3.1
shows the structure of the genomes for both sets of chimeric clones. I also used virus
derived from full length AD8 and YU-2 molecular clones with and without functional
vpu genes to evaluate the role of vpu for viral replication in macrophages.
I used the SF162 vpu in all the chimeric viruses in this study because its amino
acid sequence is most closely related to the consensus sequences of primary isolates
compared to the vpu sequence from NL4.3. The SF162 envelope was used as a vpu-
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dependent control because it has consistently been shown to be dependent upon
functional vpu [69] [139] [228]. Immunostaining of transfected 293T cells for envelope
showed that all constructs produce envelope (not shown).
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Fig. 3.1 Chimeric clones containing envelopes derived from SF162, AD8 and YU-2. a) Chimeras containing
complete env genes. The AD8 and YU-2 clones contain chimeric vpu genes. b) Chimeras containing
complete SF162 vpu genes. The AD8 and YU-2 clones contained chimeric env genes, where the leader
sequence was derived from SF162. Vpu and env sequences were introduced into the pNL4.3 background via
the EcoRI and XhoI sites.
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Infectivity of VSV G+ Viruses
Virus stocks for each of the viral clones described above were prepared by
calcium chloride transfection of plasmid DNA into 293T cells. Plasmid DNA encoding
viral or chimeric clones was co-transfected with a VSV G expression vector to create
VSV G+ virions (see Materials and Methods). Incorporation of VSV G onto emerging
virus particles subsequently conferred more efficient infection of primary macrophages.
HIV-1 virion release from 293T has been reported to be independent of vpu
[3][216]. However, to confirm that the infectivity of our vpu+ and vpu- viruses was not
influenced by production from 293T cells, I compared the number of infectious and
physical virus particles in each virus stock. Physical virus particles were measured as
reverse transcriptase (RT) activity by RT-ELISA (see Materials and Methods); infectious
virus particles were measured by titrating virus stocks onto NP2 parental cells (CD4-
CCR5-) [241]. Infectivity: RT ratios were calculated as an estimate of the infectivity per
virus particle.
Table 3.1 shows the infectivity: RT ratios for each pair of vpu+ and vpu- viruses.
The ratios for each pair are generally very close; for six out of the ten pairs, the difference
was less than two-fold (NL4.3/SF162 vpu+/- nef-, NL4.3/AD8 vpu+/-, NL4.3/AD8 vpu+/-
nef+, NL4.3/ AD8 vpu+/- nef--, AD8 vpu+/-, and YU-2 vpu+/-). For vpu+/- pairs with a
greater than two-fold difference, three of the four have a higher vpu- ratio (NL4.3/SF162
vpu+/- nef+, NL4.3/YU-2 vpu+/-, and NL4.3/YU-2 vpu+/- nef+). One pair (NL4.3/YU-2
vpu+/- nef-) had a nearly ten-fold difference between the vpu+ and vpu- virus.
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Table 3.1 Infectivity of VSV G+ virus stocks for macrophage infections
Virus Infectivity
(ffu/ml)
RT (pg/ml) Ratio
infectivity:
RT (ffu/pg)
NL4.3/SF162 vpu+ nef+ 4.6x105 47,833 9.6
NL4.3/ SF162 vpu- nef+ 8.9x105 36,441 24.4
NL4.3/SF162 vpu+ nef - 4.9x105 72,742 6.7
NL4.3/SF162 vpu- nef - 2.2x105 39,920 5.5
NL4.3/AD8 vpu+ 3.7x105 45,572 8.1
NL4.3/AD8 vpu- 4.4.x105 102,204 4.3
NL4.3/AD8 vpu+ nef+ 1.6x105 27,466 5.8
NL4.3/AD8 vpu- nef+ 4x105 107,466 3.7
NL4.3/AD8 vpu+ nef - 1.9x105 65,675 2.9
NL4.3/AD8 vpu- nef - 1.4x105 27,187 5.1
Full length AD8 vpu+ 1.1X105 58,095 1.9
Full length AD8 vpu- 1.3X105 33,272 3.9
NL4.3/YU-2 vpu+ 4.7x105 135,521 3.5
NL4.3/ YU-2 vpu- 3.6x105 47,966 7.5
NL4.3/YU-2 vpu+ nef+ 1.4x106 134,316 10.4
NL4.3/YU-2 vpu- nef+ 9x106 123,851 72.7
NL4.3/YU-2 vpu+ nef - 3.5x106 120,368 29.1
NL4.3/YU-2 vpu- nef - 5.1x105 139,771 3.6
Full length YU-2 vpu+ 1.1x104 2,136 5.1
Full length YU-2 vpu- 6.9x104 9,781 7.1
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Replication of vpu+ and vpu- HIV-1 viruses in macrophages
 Virus stocks were equalized by RT activity, and primary macrophages were
infected with equal amounts of VSV G+ replication competent viruses as described in the
Materials and Methods. Virus release resulting from multiple rounds of infection and
replication was measured over two weeks by RT-ELISA.
I first tested vpu+ and vpu- AD8 viral clones for replication in macrophages (Fig.
3.2a). The envelope of AD8 was reported to compensate for the lack of functional vpu by
enhancing virus release in HeLa cells [227]. Virus release by the vpu- AD8 virus was
variable depending on the experiment (not shown), but was consistently released at lower
levels than AD8 vpu+. Fig. 3.2a shows the maximum amount of released virions detected
in one of several experiments, reaching 60% of vpu+ AD8 release (Fig. 3.2a, left panel).
YU-2, cloned directly from brain tissue without culture, also contains a vpu start
codon mutation  yet retains the ability to infect macrophages [277] [163]. This raised the
possibility that the YU-2 envelope was vpu-independent. However, YU-2 vpu+ replicated
considerably more efficiently than vpu- YU-2 in macrophages (Fig. 3.2a, right panel).
I next tested the vpu+ and vpu- NL4.3/AD8 chimeras containing either full-length
AD8 envelopes or full-length SF162 vpu genes as described above. In both cases, vpu+
NL4.3/AD8 chimeras were consistently released at higher levels than the corresponding
NL4.3/AD8 vpu- chimeras (Fig. 3.3a, 3.3b), regardless of the strategy used to construct
the chimeric viruses. Similarly, NL4.3/YU-2 vpu+ was consistently released from
macrophages at higher levels than NL4.3/YU-2 vpu-, again regardless of whether the
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chimeric viruses carried full length or chimeric vpu or envelope sequences (Fig. 3.3a,
3.3b).
Fig. 3.4 shows in situ immunostaining for p24 at different times after infection of
macrophages. Both vpu+ and vpu- viruses infected macrophages, as can been seen by the
presence of stained cells. Wells of macrophages infected with vpu- viruses, however, have
fewer infected cells than wells infected vpu+ viruses 96 hours post infection.
I tested the possibility that the known vpu-dependent envelope could be forced to
become vpu-independent when passaged multiple times through primary macrophages. A
chimeric virus based on the NL4.3/SF162 described above with 50 amino acids removed
from the beginning of vpu (NL4.3/SF62 delta vpu) was constructed. I infected
macrophages with a high dose of this chimeric virus pseudotyped with VSV G. One week
post-infection, supernatants were removed and used to infect fresh macrophages. This
was repeated 4 times for a total of 5 passages. RT activity in the supernatants used for
each infection was quantified. After the initial passage, the amount of virus in the
supernatants was too low to effectively infect macrophages (Fig. 3.5).
The experiments described in Figs. 3.2, 3.3, and 3.5 were carried out multiple
times on different batches of macrophages. The graphs shown here are representative of
multiple experiments.
In summary, I found that the full-length vpu- AD8 consistently replicated with
lower efficiency in macrophages compared to vpu+ AD8. Using chimeric viruses, I was
unable to show that the AD8 envelope could compensate for the lack of a functional vpu.
In addition, neither the full length YU-2 nor its envelope compensated for the lack of a
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functional vpu. I was unable to determine if the SF162 envelope can become vpu-
independent due to low levels of virus output from macrophages.
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Fig. 3.2 Effect of vpu mutations on virion release from macrophages. Macrophages were spinoculated with
equal amounts of virus, and incubated for 2 weeks. (a) AD8 and YU-2. (b) NL4.3/SF162. In all cases, vpu+
viruses were released from macrophages at higher levels than vpu- viruses. These graphs are representative
of multiple assays.
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Fig. 3.3 Effect of vpu mutations on virion release from macrophages using chimeric constructs.
Macrophages were spinoculated with equal amounts of virus and incubated for 2 weeks. (a) NL4.3/AD8
and NL4.3/YU-2 constructs carrying full-length env and chimeric vpu genes. (b) NL4.3/AD8 and
NL4.3/YU-2 constructs carrying full-length SF162 vpu genes and chimeric env genes. In all cases, vpu+
viruses were released from macrophages at higher levels than vpu- viruses. These graphs are representative
of multiple assays.
0
1000
2000
3000
4000
NL4.3/AD8
0 50 100 150 200 250 300
0
10000
20000
30000
40000
50000
0 50 100 150 200 250 300
NL4.3/YU-2
Time (hours)
0
15000
30000
45000
60000
75000
0 50 100 150 200 250 300
NL4.3/YU-2
0
10000
20000
30000
NL4.3/AD8
0 50 100 150 200 250
a. Full length env, chimeric vpu
b. SF162 vpu, chimeric env
RT
 (p
g/m
L
RT
 (p
g/m
L)
Time (hours)
env
vpu
env
vpu
env
vpu
env
vpu
vpu+
vpu-
46
Fig. 3.4 Immunostaining of macrophages infected with vpu+ and vpu- HIV-1. Macrophages were infected
with vpu+ and vpu- NL4.3/SF162, NL4.3/ AD8, and AD8. Infected cells were fixed and immunostained for
p24 at 24-hour intervals. Blue-stained cells indicate infection. These micrographs show that vpu+ viruses
confer more efficient spread and formation of small syncytia. Magnification, x60.
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Fig. 3.5 Passage of chimeric viruses through macrophages. Macrophages were infected with a high dose of
virus, and spinoculated. One week post-infection, supernatants were removed, and used to infect fresh
macrophages. The RT of the infecting supernatant was quantified. Passage number 0 represents the first
macrophage infection. Due to the low yield of virus particles after the initial infection, we were unable to
force the SF162 envelope to become vpu-independent in macrophages. This graph is representative of
multiple assays.
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Short term virus release from infected macrophages
The infectivity assays described above followed virion release from macrophages
during several rounds of replication over two weeks. It was possible that the vpu-
independent phenotype reported for full-length AD8 [227] is more pronounced in early
rounds of replication. I therefore examined whether the AD8 envelope conferred a vpu-
independent phenotype when viral replication was limited to a single round.
Macrophages were infected with high doses of virus, and treated with indinavir sulfate
(IVS, a protease inhibitor) 3 hours after infection to prevent subsequent rounds of
infection. Virus release was measured over 4 days by RT ELISA.
In the presence of 10 µM IVS, vpu+ viruses were released to higher levels than
vpu- viruses (Fig. 3.6). I observed this phenotype for the SF162 and AD8 chimeras, as
well as for full-length AD8.
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 Fig. 3.6 Inhibition of viral spread by IVS. Macrophages were infected with a high dose of virus,
spinoculated, treated with 10 µM IVS and incubated for 4 days. In all cases, vpu+ viruses were released at
higher levels than vpu- viruses. These graphs are representative of multiple assays.
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The Role of Nef
The strategy used to create the chimeric clones used in these studies resulted in
chimeric nef genes (34 amino acids from AD8 or YU-2 and 162 amino acids from NL4.3;
Fig. 3.1). To determine whether nef influenced the phenotypes described above, I
introduced a premature stop codon in nef at the XhoI I site into the vpu+ and vpu- chimeric
viral clones (Fig. 3.1b). Virus derived from these clones was then used to infect
macrophages, and virus released into the supernatant was measured over two weeks by
RT ELISA as described above.
NL4.3/SF162 and NL4.3/YU-2 chimeras carrying mutated nef genes
(nef -) were released from macrophages at low levels similar to the vpu- chimeras, while
the vpu+ nef+ counterparts replicated efficiently (Fig. 3.7a, 3.7b).  Curiously, the vpu+ nef--
NL4.3/AD8 chimera varied in virus release depending on experiment.  In one
experiment, the vpu+ nef-- NL4.3/AD8 chimera replicated as efficiently as the vpu+ nef+
chimera (Fig. 3.7c, right panel), while in a second experiment, virus release was low and
comparable to the vpu- nef- chimera (Fig. 3.7c, left panel).
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Fig. 3.7 Effect of nef on vpu phenotypes. Macrophages were spinoculated with equal amounts of vpu+/vpu-,
nef+/nef- viruses and incubated for 2 weeks. (a) NL4.3/SF162; (b) NL4.3/YU-2; (c) NL4.3/AD8. Results
from two separate but representative experiments are shown in the left and right panels. For NL4.3/SF162
(a) and NL4.3/YU-2 (b), the presence of non-functional vpu, nef or both resulted in severely reduced virus
release from macrophages. For NL4.3/AD8 (c), the presence of non-functional vpu, nef, or both resulted in
reduced viral release for some experiments (left panel). However, virus release for vpu+ was observed even
in the context of nef- in other experiments (right panel). These graphs are representative of multiple assays.
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Discussion
  In this study, I determined that neither the AD8 nor the YU-2 envelope was able
to compensate for the lack of functional vpu in terms of virus release from macrophages.
Release of vpu- viruses from macrophages was consistently lower than their vpu+
counterparts (Fig. 3.2, 3.3 and 3.7). However, release of vpu- AD8 was variable, reaching
60% of vpu+ AD8 in one experiment. Short term virus release experiments showed that
lower viral release by vpu- viruses is primarily due to a defect in release, but is
compounded by reduced viral spread (Fig. 3.4 and 3.6). Nef does not compensate for the
lack of functional vpu in HIV-1 replication in macrophages (Fig. 3.7).
Vpu’s ability to enhance the release of virus particles is usually critical for HIV-1
replication in macrophages.  Mutation of the vpu start codon occurs at low frequency
during PBMC culture of HIV-1 isolates in vitro [69]. Thomas et al. described defects in
the vpu genes present in several vpu-envelope sequences amplified from brain tissue,
where macrophage lineage cells are the main targets for infection [255]. YU-2, a highly
macrophage-tropic strain cloned directly from brain tissue of an AIDS patient, also
carries a vpu start codon mutation [163]. Schubert et al. reported that the envelope of the
HIV-1 AD8 isolate carried determinants that could compensate for the lack of vpu [227].
These observations led to the hypothesis that loss of vpu function in vivo may be
compensated by adaptive mutation in envelope. Loss of vpu function could be
advantageous in some environments, as it was reported to result in an increase in
envelope synthesis [227] [245]. Here, I investigated whether the envelopes of AD8 and
YU-2 could compensate for loss of vpu function for virus release and replication in
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primary macrophage cultures. These results do not lend support to a role for envelope in
compensating for a loss of vpu function in macrophages.
The data presented here appear to conflict with the study of Schubert et al., which
showed that AD8 viruses with and without a mutated vpu start codon replicate efficiently,
and to equivalent levels in primary macrophages [227]. In the same study, Schubert et al.
used a pseudovirion system to show that the AD8 envelope could enhance virion release
from HeLa cells. Interestingly, several groups have also reported that the HIV-2ROD
envelope enhanced virion release [2] [192] [31]. Therefore, it seems reasonable that some
HIV-1 envelopes, e.g. AD8, may have evolved to perform the same virion-release
function. It is unclear why I did not observe rescue of vpu start codon mutations for the
AD8 envelope. Using non-chimeric AD8 infectious clones, vpu- AD8 did confer
significant (although variable) levels of virion release in primary macrophages, but
always less efficiently than vpu+ AD8. However, while Schubert et al. implicated the
AD8 envelope as the determinant for vpu-independent virion release by using
NL4.3/AD8 chimeras similar to those described here, I did not. In this study, I used
primary macrophages prepared from blood monocytes by elutriation [107] [234] similar
to those used by Schubert et al.. Both studies also monitored multiple rounds of viral
replication in macrophages. I produced viruses from transfected 293T cells for
macrophage infections, whereas Schubert et al. produced them in HeLa cells. HeLa cells
carry the host-cell restriction overcome by vpu  whereas 293T cells do not [190] [263] [3]
[216]. vpu- viruses produced from HeLa cells may have altered envelope content and
infectivity compared with virus particles from 293T cells. However, such a difference
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would only affect the initial infection stage, and cannot explain the enhanced virion
release observed here for vpu+ viruses compared with the equivalent virion release of
Schubert et al. for vpu+ and vpu- viruses over multiple rounds of replication in
macrophages. I attempted to produce virus stocks from HeLa cells, like Schubert et al.
Unfortunately, the transfection efficiency was too low to produce enough virus to infect
macrophages.
The apparent differences between my data and the data in the previous report by
Schubert et al. led me to undertake several control experiments. First, I assessed
infectivity: particle ratios of the VSV G+ virions that were produced from 293T cells to
make certain that vpu- virions conferred similar levels of infectivity as vpu+ virions. I
confirmed that virus production in 293T cells is not affected by vpu.  Next, I evaluated
virus release in a single replication cycle and in a spreading infection to confirm that
rescue of virion release by the AD8 envelope did not occur early before being
overwhelmed by cell:cell spread. Low virus release by AD8 vpu- viruses is not due to the
lack of infected cells, but results partly from decreased spread. Therefore, increased virus
release for AD8 vpu+ viruses is partly due to the spread to, and infection of, more
macrophages. I also discounted an effect by nef, which, like vpu, downregulates CD4
[165].   These control experiments failed to alter my conclusion that the envelopes
studied here did not affect vpu- virion release. Finally, I tested vpu+ and vpu- chimeric
viruses constructed in two different ways resulting in either full-length SF162 vpu and
chimeric env, or chimeric vpu. However, the different AD8 or YU2 chimeric constructs
consistently failed to show that the loss of vpu function could be rescued by either AD8
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or YU-2 envelope for macrophage replication.
In this study, I focused entirely on the effects of vpu on HIV-1 replication in
primary macrophages and have avoided studying HeLa cells. HeLa cells are frequently
used to examine the effects of vpu defects on viral replication [2] [227] [263]. However,
while HeLa cells are valuable tools for studying events in vitro, it is unclear whether they
are representative of any cell type targeted by HIV in vivo. A rapidly dividing culture of
HeLa cells may not accurately model a culture of terminally differentiated macrophages.
Neil et al. reported that vpu prevents the internalization of nascent virions by tetherin
from the cell surface in HeLa cells conferring more efficient release of virions [190]. In
contrast, newly budded virions from primary macrophages are predominantly found in
intracellular vesicles even when HIV-1 carries vpu [199]. It is unclear whether tetherin or
additional factors expressed in macrophages prevent virus release, and are overcome by
vpu. These observations suggest that the mechanisms that lead to virion endocytosis in
the absence of vpu may be significantly more potent in macrophages compared to HeLa
cells. Therefore, the requirement for vpu for virus release in macrophages may be
significantly more robust than the vpu requirement in HeLa cells. This possibility could
explain the inefficient replication in macrophages by vpu- AD8 observed here, if the
putative vpu-independent AD8 envelope could not overcome the macrophage-imparted
block on virion release.
I noted considerable variation from macrophage batch to batch, which presumably
reflected macrophage donor variation. Some batches of macrophages failed to yield
sufficient virus particles to provide meaningful results for my experiments.
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Immunostaining in situ for p24 at the end of these assays showed that low levels of
infected cells were the cause. Whether low infectivity was due to poor infection conferred
by VSV G, or to post-entry restrictions is unclear. The fluctuating results seen with the
NL4.3/AD8 vpu+ nef- virus may also be due to variation between batches of macrophages.
In summary, using chimeric viruses based on NL4.3, I did not find evidence that
the AD8 envelope can significantly rescue loss of vpu for macrophage replication.
Moreover, the envelope from the YU-2 clone that carries a vpu start codon mutation, and
is highly macrophage-tropic, also failed to confer macrophage replication.  The variable
replication in macrophages observed for vpu- AD8 suggests the presence of a viral
determinant (presumably not envelope) that partially compensates for vpu loss. However,
these results do not yet support the presence of fully vpu-independent HIV-1 variants that
could preclude the development of vpu inhibitors for therapy.
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Chapter IV: HIV-1 macrophage tropism varies
substantially over the course of infection
Introduction
The Human Immunodeficiency Virus (HIV) is an enveloped virus with
glycoprotein spikes inserted into its plasma membrane [274] [295] [81]. These
glycoprotein spikes are encoded by the virus’ env gene, and are synthesized as a
polyprotein, gp160 [6]. gp160 is proteolytically digested by cellular furin/ furin-like
proteases into gp120 and gp41 in the Golgi [116]. gp120 is found on the outside of the
virus particle, while gp41 is inserted into the plasma membrane. gp120 and gp41 are
weakly associated via a noncovalent bond on the virus particle [206] [122].  gp120 is
responsible for interacting with CD4, the main host cell receptor, and either CCR5 or
CXCR4, the coreceptor, triggering a series of conformational changes in gp41 that causes
fusion of the virus and host cell membranes and subsequent infection [144] [182] [63]
[48] [71] [73] [219].
Macrophages are an important reservoir of virus during infection, especially
during the late stages of infection, when CD4+ T cell counts decline sharply [133].
Viruses that use CCR5 as a coreceptor are called R5-tropic; R5-tropic viruses are also
frequently described as macrophage tropic. However, wide variation in R5-tropic viruses’
ability to infect macrophages has been reported [68] [150] [239]. Non-macrophage-tropic
R5 viruses are prevalent in immune tissue and blood, while macrophage tropic viruses are
readily found in brain tissue, especially in HIV+ patients diagnosed with dementia [203]
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[111]. R5 viruses from late stages of disease have been reported to be more macrophage
tropic [113] [162] [257].
Macrophages express low levels of CD4 and CCR5 [156]. R5 macrophage tropic
viruses have an enhanced ability to use these low levels of CD4 [201] [203].
Determinants of R5 macrophage tropism have been mapped to residues in the CD4
binding site on gp120, and to residues likely to impact exposure of the CD4 binding site
[78] [79] [202]. These structural changes may have consequences for neutralizing
antibodies.
HIV-specific antibodies can be detected in infected individuals 4-8 weeks after
infection. The antibody response against gp120 can be very strong: a variety of antibodies
to different epitopes are produced to high levels [1] [5]. However, this response is not
effective because the virus is able to quickly evolve to avoid binding of antibodies.
Escape from these neutralizing antibodies may be conferred by mutations in the
sequences encoding antibody epitopes. Escape can also be conferred by envelope changes
that result in the shielding of epitopes, either by the variable loops or glycan groups [95]
[169] [146] [273] [252]. Conserved gp120 epitopes that are critical for interactions with
receptors may be protected in these ways. Therefore, neutralizing antibodies in immune
tissues may act as modulators of virus tropism by selecting for variants that carry
envelopes with critical receptor binding sites protected. When these sites are protected,
viruses are less likely to use low levels of CD4 and CCR5, as on macrophages.
It has been reported that macrophage tropism correlates with increased resistance
to inhibition by monoclonal antibodies that bind CD4 [202]. This suggests that these
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viruses’ gp120s have an increased affinity for CD4, allowing them to utilize the low
levels of CD4 on macrophages. Macrophage tropic R5 viruses are frequently sensitive to
b12, a human monoclonal antibody that targets a region proximal to the CD4 binding site
on gp120 [202] [38]. This suggests that macrophage tropic envelopes may also have a
more open conformation around their CD4 binding sites in gp120, allowing greater
access to neutralizing antibodies like b12. Neutralizing antibodies that target the CD4
binding site may confer a strong selection for virus variants that have this site protected
[164].  I hypothesize that the presence of neutralizing antibodies drives the development
of viral variants that are unable to use low levels of CD4, as on macrophages.
Here, I evaluated whether macrophage tropism of patient envelopes varies early in
infection before and after autologous and heterologous antibodies appear. Using HXBc2
chimeric viruses containing gp120 sequences cloned from patient PBMC at different time
points during disease, I evaluated if these patient envelopes were able to use low levels of
CD4 in cell lines and macrophages. I compared when macrophage-tropism appeared to
when autologous and heterologous neutralizing antibodies appeared, and found that R5
macrophage tropism varied substantially in the patients studied here.
Results
Characteristics of patients and envelopes
HIV-1 HXBc2 clones containing gp120 sequences were provided by Marlen
Aasa-Chapman (University College London). Four homosexual men (MM1, MM4, MM8
and MM23) with symptomatic primary HIV-1 infection were studied; characteristics of
their disease have been published previously [1]. Briefly, patients developed influenza-
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like symptoms between 12 and 35 days post high risk exposure incident, and
subsequently developed HIV-1 specific antibodies. All patients remained antiretroviral
therapy naïve throughout the study. Patients were removed from the study when they
started antiretroviral therapy.
PBMC and plasma samples were collected when patients presented with
influenza-like symptoms, then at approximately three-month intervals. Envelopes,
specifically the gp120 segment, were amplified by PCR from PBMC, and cloned into the
HXBc2 backbone via unique BstEII and MluI restriction enzyme sites by M. Aasa-
Chapman.  This created full-length replication competent chimeras. Heteroduplex
mapping was used to determine if the cloned patient gp120s represented the bulk of the
viral population. The majority of the cloned envelopes were representative of the major
species circulating at the time of sampling [1].  Table 4.1 summarizes the characteristics
of the patients and envelopes used in this study.
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Table 4.1 Summary of Patient Envelope Characteristics
Patient ID Clone # Isolation Day Coreceptor Usage
1.2.1 28 R5
1.2.3 28 R5
1.5.58 84 R5
1.12.1 833 R5
1.12.4 833 R5
1.12.7 833 R5
1.12.8 833 R5
1.20.B 2702 R5
1.20.C 2702 R5
1.20.E 2702 R5
1.20.F 2702 R5
1.20.I 2702 R5
1.20.J 2702 R5
MM1
1.20.K 2702 R5
4.1.33 17 R5
4.1.34 17 R5
4.10.1 493 R5
4.10.3 493 R5
4.10.4 493 R5
4.10.7 493 R5
4.12.1 844 R5
4.12.4 844 R5
4.12.6 844 R5
MM4
4.12.7 844 R5
8.2.50 12 R5
8.2.51 12 R5
8.4.51 32 R5
8.8.1 608 R5
8.8.3 608 R5
8.8.4 608 R5
8.8.8 608 R5
8.9.B 957 R5X4
8.9.D 957 R5X4
8.9.H 957 R5X4
8.9.I 957 R5X4
MM8
8.9.J 957 R5X4
23.2.D 15 R5
23.2.E 15 R5
23.2.F 15 R5
23.2.H 15 R5
23.8.12 316 R5
23.8.18 316 R5
23.12.3 316 R5
MM23
23.12.7 316 R5
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Autologous and heterologous neutralization by patient plasma
Serum samples from each patient had previously been evaluated for the presence
of antibodies that neutralized envelopes derived from the same patient (autologous
neutralization) [1]. Patient MM8 developed autologous neutralizing antibodies between 2
and 3 months post infection. The remaining patients did not develop autologous
neutralizing antibodies until at least 4 months post-infection. Neutralizing antibody titers
were between 1:10 and 1:80 [1]. Non-neutralizing HIV+ antibodies were detected
between 12 and 28 days post-infection [1].
The ability of these patient antibodies to neutralize the T-cell line adapted strain
IIIB was also assessed (heterologous neutralization).  Patient antibodies were typically
unable to neutralize IIIB until 3 months or more after the onset of symptoms (Fig. 4.1b,
4.2b, and 4.4b). This neutralization also tended to be weak (titers of < 1:10, up to 1:20)
[1].  Patient MM8 did not develop heterologous neutralizing antibodies during the study
(Fig. 4.3b).
Several of the patient envelopes were found to be neutralization sensitive to b12.
These were: 4.10.1, 4.10.3, 8.8.3, 8.8.8, 23.8.12, and 23.12.7 (M. Aasa-Chapman,
personal communication).
Infection of CD4+ CCR5+  cell lines and macrophages by patient chimeras
I assessed the titers of these patient envelopes on a cell line that expressed low
levels of CD4 (RC49 cells), as well as primary macrophages. I also used a cell line that
expressed high levels of CD4 (TZM-bl cells) to determine the titers of the patient chimera
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stocks. I compared the titers of these stocks on RC49 cells and macrophages to their titers
on TZM-bl cells to determine if the patient envelopes were macrophage-tropic.
Most viruses had high titers on TZM-bl cells (1 x 103 to 1 X 104 ffu/mL) (Fig.
4.1a, 4.2a, 4.3a, and 4.4a, red bars). The majority of viruses were unable to infect RC49
cells or macrophages efficiently (Fig. 4.1a, 4.2a, 4.3a, and 4.4a, blue bars or black bars,
respectively). For this study, macrophage-tropic viruses were defined as viruses that had
a minimum titer of 1000 ffu/mL on macrophages (see Appendix A for details). By this
definition, the following viruses are macrophage-tropic: Patient MM1 1.2.3, 1.20.B,
1.20.E, 1.20.I; Patient MM4 4.10.3, 4.10.7; Patient MM8 8.2.50, 8.8.3, 8.8.4, 8.9.B,
8.9.D8.9.H, 8.9.I, 8.9.J. Patient MM23 did not develop any macrophage-tropic envelopes.
These macrophage-tropic envelopes did not cluster at any particular time point, but were
found at different time points throughout infection.
Variation in macrophage tropism was seen between envelopes derived from the
same PBMC sample. Three of the seven envelopes from PBMC collected on day 2702
from Patient MM1 were macrophage tropic (Fig. 4.1a). Two of the four envelopes
derived from PBMC collected on day 493 from Patient MM4 were macrophage tropic
(Fig. 4.2a). Two of the four envelopes derived from PBMC collected on day 608 from
Patient MM8 were macrophage tropic. All five envelopes from day 957 were
macrophage tropic (Fig. 4.3a).
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Fig. 4.1 Patient MM1 a)Titers on TZM-bl, RC49, and macrophages. TZM-bl cells, RC49 cells, and macrophages
were infected, fixed and stained as described in the Materials and Methods. The titer for each virus was then
calculated. Blue stars indicate macrophage-tropic viruses. b) heterologous neutralization of IIIB Neutralization
assays were done by M. Aasa-Chapman at University College London. Neutralization was calculated by IC90.
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Fig. 4.2 Patient MM4 a) Titers on TZM-bl, RC49, and macrophages. TZM-bl cells, RC49 cells, and macrophages
were infected, fixed and stained as described in the Materials and Methods. The titer for each virus was then
calculated. Blue stars indicate macrophage-tropic viruses. b) heterologous neutralization of IIIB. Neutralization
assays were done by M. Aasa-Chapman at University College London. Neutralization was calculated by IC90.
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Fig. 4.3 Patient MM8 a)Titers on TZM-bl, RC49, and macrophages. TZM-bl cells, RC49 cells, and macrophages
were infected, fixed and stained as described in the Materials and Methods. The titer for each virus was then
calculated. Blue stars indicate macrophage-tropic viruses. b) heterologous neutralization of IIIB. Neutralization
assays were done by M. Aasa-Chapman at University College London. Neutralization was calculated by IC90.
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Fig. 4.4 Patient MM23 a)Titers on TZM-bl, RC49, and macrophages. TZM-bl cells, RC49 cells, and macrophages
were infected, fixed and stained as described in the Materials and Methods. The titer for each virus was then
calculated. Blue stars indicate macrophage-tropic viruses. b) heterologous neutralization of IIIB. Neutralization
assays were done by M. Aasa-Chapman at University College London. Neutralization was calculated by IC90.
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The effect of HXBc2 gp41 on macrophage tropism
In the chimeras used in this study, only the gp120 segment of envelope from
patient PBMC was cloned into the HXBc2 backbone. It was possible that the HXBc2
gp41 could influence the phenotype conferred by patient gp120s, and their abilities to use
low levels of CD4. I replaced the gp41 of a control virus, HXBc2/ YU-2 gp120, with the
gp41 of YU-2, a macrophage-tropic virus. The infectivity of this envelope was compared
with that of two other envelopes, B33 and LN85. These gp160s had previously been
cloned into NL4.3, and their macrophage-tropism had been well-characterized. B33 is
macrophage-tropic, while LN85 is not [201].
HXBc2/YU-2 gp120 and HXBc2/ YU-2 gp160 infected RC49 cells and
macrophages with similar efficiencies (Fig. 4.5). NL4.3/B33 also infected RC49 cells and
macrophages, while NL4.3/LN85 did not, as expected (Fig. 4.5).
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Discussion
Here, I investigated the macrophage tropism of envelopes derived from patient
PBMC from different time points during infection. For Patient MM1, macrophage tropic
envelopes appeared at day 28 (1.2.3) and day 2702 (1.20.B, 1.20.E, 1.20.I) (Fig. 4.1a).
For Patient MM4, macrophage tropic envelopes appeared at day 493 (4.10.3, 4.10.7)
(Fig. 4.2a).  For Patient MM8, macrophage tropic envelopes appeared at day 12 (8.2.50,
day 608 (8.8.3, 8.8.4), and day 957 (8.9.B, 8.9.D, 8.9.H, 8.9.I, 8.9.J) (Fig. 4.3a). Patient
MM23 had no macrophage tropic envelopes appear (Fig. 4.4a) Replacement of the gp41
in the control chimera HXBc2/ YU-2 gp120 did not affect macrophage-tropism (Fig.
4.5).
 The viruses used in this project were gp120s amplified from patient PBMC, then
cloned into an HIV-1 HXBc2 background. This approach results in chimeric envelopes
that carry gp41 from HXBc2. It has been show recently that determinants in gp41 may
impact the coreceptor tropism of gp120 [131]. It is therefore possible that the gp41 of
HXBc2 impacts the tropism of gp120 sequences cloned into it. To ascertain whether
HXBc2 gp41 affected the properties of a heterologous gp120, I removed the HXBc2 from
HXBc2/ YU-2 gp120, and replaced it with that from YU-2 to create HXBc2/YU-2
gp160. I saw no difference in this virus’ ability to infect TZM-bl cells, RC49 cells, or
macrophages compared to HXBc2/YU-2 gp120 (Fig. 4.5). The HXBc2 molecular clone
also has the unique feature of having a non-functional vpu gene, due to a mutated start
codon (ATG to ACG). It is possible that this may also impact the properties of gp120s
cloned into HXBc2. Both of these observations should be taken into account when
interpreting results using this molecular clone.
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Patients developed autologous neutralizing antibodies as early as 2 months post
infection (Patient MM8), and as late as 4 months post infection (Patients MM1 and MM4,
and MM23). Non-neutralizing HIV+ antibodies appeared much earlier, between 12 and
28 days in infection. In two patients, MM1 and MM8, macrophage-tropic envelopes
appeared after the initial antibody response, but before the appearance of autologous
antibodies. In Patients MM1, MM4, and MM8, macrophage-tropic envelopes continued
to appear after autologous neutralizing antibodies.  These results suggest that the
presence of neutralizing antibodies is not solely responsible for driving envelopes away
from macrophage-tropism. It is likely that macrophage-tropism gives viruses an
evolutionary advantage in vivo. One of these advantages may be that macrophages
provide an excellent reservoir for HIV-1 infection.
It has been reported that enhanced macrophage-tropism can be conferred by
changes in the CD4 binding site in gp120 [78] [79] [202]. These changes increase
envelope’s affinity for CD4, and consequently confer infection of cells expressing low
levels of CD4. In addition, better exposure of the CD4 binding site may have a similar
effect on gp120:CD4 affinity. R5 macrophage-tropic envelopes may be able to use
different isoforms of CD4 or CCR5 on macrophages, or be more efficient at using
attachment factors such as syndecans and C-type lectins [256]. Residues that enhance the
fusogenicity of envelopes may also be responsible for macrophage-tropism. Sterjovki et
al. reported that an asparagine at position 362 in the C3 region contributed to enhanced
fusogenicity of R5 envelopes [246]. The loss of a N-linked glycosylation site at position
386 in the V4 loop has been found to enhance macrophage-tropism of envelopes [79].
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The V3 loop, responsible for coreceptor usage, may also have a role in envelopes’ ability
to bind to low levels of CCR5. There are still other undefined determinants of
macrophage-tropism in gp120.  None of the envelopes described here carry the N283
motif, which has been reported to confer increased CD4 affinity and macrophage tropism
[78] [79]. Two of the four envelopes from day 608 from Patient MM8 are macrophage-
tropic. An alignment of these four sequences did not reveal consistent differences that
could account for their distinct macrophage-tropism properties. It is likely that the
macrophage-tropic envelopes presented here have still undefined determinants of
macrophage-tropism, such as increased fusion ability.
In conclusion, the appearance of macrophage-tropic envelopes vary substantially
over the course of infection in the patients studied here. These envelopes appeared before
and after autologous neutralizing antibodies. This suggests that the presence of
neutralizing antibodies does not necessarily force envelopes away from macrophage-
tropism. Retaining macrophage-tropism, despite antibody pressure, must give HIV an
evolutionary advantage. As macrophages provide a reservoir for infection, it would be
valuable to examine how envelopes retain macrophage-tropism over time.
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Chapter V: HIV-1 gp41 cytoplasmic domains of two
envelopes carry determinants of virion infectivity
Introduction
The Human Immunodeficiency Virus (HIV) is an enveloped virus with
glycoprotein spikes inserted into its plasma membrane [274] [295] [81]. These
glycoprotein spikes are encoded by the virus’ env gene, and are synthesized as a
polyprotein, gp160 [6]. gp160 is proteolytically digested by cellular furin/ furin-like
proteases into gp120 and gp41 in the Golgi [116]. gp120 is found on the outside of the
virus particle, while gp41 is inserted into the plasma membrane. gp120 and gp41 are
weakly associated via a noncovalent bond on the virus particle [206] [122].  gp120 is
responsible for interacting with CD4, the main host cell receptor, and either CCR5 or
CXCR4, the coreceptor, triggering a series of conformational changes in gp41 that causes
fusion of the virus and host cell membranes and subsequent infection [144] [182] [63]
[48] [71] [73] [90] [219]. These conformational changes in gp41 allow the fusion peptide
in gp41 to insert into the target cell membrane. The 6-helix bundle brings the viral and
cell membranes together, and the viral core is released into the cytoplasm of the cell
[276] [96] [221] [70] [75] [76].
The cytoplasmic domain of gp41 contains several functional motifs responsible
for assembly of envelope onto virus particles, and infectivity. Fig. 5.1 shows a schematic
of gp41 in the virus plasma membrane, and Table 5.1 summarizes theses motifs. gp41
can be broken into 3 general domains: the ectodomain, the transmembrane domain, and
the cytoplasmic domain. The ectodomain contains the fusion peptide and heptad repeats,
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responsible for forming the 6-helix bundle needed to bring the viral and host cell
membranes together for fusion and entry [42] [275]. It also carries determinants for
interacting with gp120 [122]. The transmembrane domain anchors gp41 in the viral
plasma membrane [267].
The cytoplasmic domain contains many functional motifs. The YSPL motif is an
endocytosis signal. It recruits AP-2 in clathrin-coated pits for this purpose [32] [27] [21]
[194]. The Kennedy/ Dimmock loop has no known function; however, it has been
proposed to loop outside the viral plasma membrane and form a neutralizing antibody
epitope [51] [43]. There are two palmitoylation sites at positions 764 and 837. These
palmitoylation sites are responsible for envelope targeting to lipid rafts, which is an
important step in virus assembly at the host cell membrane. These are relatively
conserved cysteines; the 764 residue is more conserved. If these cysteines are mutated to
amino acids with bulky hydrophobic side chains, infectivity is retained [213] [287]. The
PRA1 binding site binds the cellular protein PRA1, a protein associated with Golgi
membranes [85]. The YW motif binds TIP47, a cellular protein responsible for bringing
gag and envelope together, and recruiting rab9, which is involved in vesicular trafficking
[26] [166] [45]. The dileucine motif at the end of the cytoplasmic domain is responsible
for binding AP-1 in clathrin-coated pits [286].
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Fig. 5.1 Schematic of gp41 cytoplasmic domain, with locations of functional domains.
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gp41 Cytoplasmic
Domain Motif
Position Function Reference
YSPL 712-715 Endocytosis signal,
recruits AP-2 in
clathrin-coated pits
[32] [27] [21] [194]
Kennedy/Dimmock
Loop
724-745 Unknown [51] [43]
LI 755-756 Dileucine motif [286]
C 764 Palmitoylation site [213] [287]
LLP 2/3 770-796 Lentilytic peptides;
interact with
membranes
[186] [145]
PRA1 binding site 766-807 Interacts with
PRA1, a protein
associated with
Golgi membranes
[85]
YW 802-803 TIP47 binding site [26] [166] [45]
LLP-1 828-856 Lentilytic peptide;
interacts with
membranes
[186] [185]
F 837 Palmitoylation site [213] [287]
LL 855-856 Dileucine motif [286]
Table 5.1: Summary of functional motifs in the cytoplasmic domain of gp41
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Our lab has previously reported on two envelopes derived from two separate
tissues from the same patient. One envelope from brain, B33, confers high levels of
infectivity, while the other envelope from lymph node, LN40, confers low levels of
infectivity despite being fusogenic in cell:cell assays. When the entire gp41 of LN40 is
replaced with that of B33, there is a restoration of infectivity [24]. I hypothesize that
there are determinants in the gp41 of LN40 that cause its weak infectivity.
Here, the determinants of infectivity in gp41 were investigated using these two
envelopes, B33 and LN40. Chimeric envelopes as well as point mutations were
constructed. I found that no chimera or combination of point mutations completely
restored infectivity; however changes in the first palmitoylation site at position 764, the
Pr55gag binding region at positions 787 and 788, combined with restoration of the
dileucine motif at position 856 increased LN40 infectivity.
Results
Introduction to B33 and LN40 and construction of chimeras
B33 and LN40 are envelopes derived from two separate tissues from the same
patient. B33 was derived from brain tissue; LN40 was derived from lymph node tissue
[201]. B33 envelope confers high levels of infectivity to pseudovirions, while LN40
envelope confers low levels of infectivity (Fig. 5.2a). Both of these envelopes are
fusogenic in cell:cell fusion assays (Fig. 5.2b).
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Fig. 5.2 Characteristics of B33wt and LN40wt. a) Ratio of ffu: RT for B33 wt and LN40 wt. Virus stocks
were titrated onto TZM-bl cells. Cells were fixed and stained 48 hours post-infection; stained cells were
counted, and the ffu/mL value was calculated. The RT (in pg/mL) of the stocks was quantified by RT-
ELISA. b) Cell:cell fusion assay. 293T cells were transfected with viral DNA;  24 hours later transfected
cells were mixed with TZM-bl cells.Cells were fixed and stained when syncytia appeared. See text and
Materials and Methods for experimental detail. B33wt-transfected cells form syncytia more quickly (4
hours) than LN40wt-transfected cells (6 hours).
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There are fourteen amino acid differences between B33 and LN40 in gp41. These
differences are highlighted in Fig. 5.3. Several are in, or near, functional domains. There
are three differences within the transmembrane domain, one at the palmitoylation site
(position 764), two at a potential Pr55gag binding site (positions 787 and 788), two
proximal to the TIP47 binding site (positions 687 and 690), and one in the dileucine motif
at the end of LLP-1 (position 856). The remaining five differences are not in any defined
functional domains.
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Fig. 5.3 Amino acid alignment of B33 and LN40 gp41 sequences. Important functional domains are
highlighted in red. Differences between B33 and LN40 are circled. Unique enzyme sites used to construct
chimeras are marked in green. Reference amino acid numbers are on the right.
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Several chimeras of B33 and LN40 envelopes were constructed using unique
MfeI, SalI, and BlpI sites (Fig. 5.4a). I constructed two chimeras using the MfeI site at
the start of gp41, and the BlpI site at the end of gp41. One chimera has the gp120 of B33,
and the complete gp41 of LN40; the other has the reverse (Fig. 5.4b). I replaced the RR
in LN40/B33wt MfeI-BlpI at positions 787 and 788 with HS (Fig. 5.4b). This was to
assess the effects of these potentially important gag binding sites on infectivity.
I constructed a second set of chimeras using the SalI site just upstream of the
palmitoylation site at position 764. One chimera has the SalI-BlpI fragment of LN40
placed into B33; the other has the reverse (Fig. 5.4c). Again, I replaced the RR in
LN40/B33 SalI-BlpI with HS (Fig. 5.4c).
The following results are all from using env+ pseudovirions. B33, LN40, their
chimeras, or their variant envelopes are all in the pSVIIIenv expression vector. These
vectors are co-transfected with pNL4.3 env- to create envelope+ pseudovirons (see
Materials and Methods for details).
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Fig. 5.4 Schematics of B33 and LN40 chimeras used in this study. a) B33 and LN40 wt, with unique
restriction sites marked, b) B33/LN40 MfeI-BlpI chimeras, c) B33/LN40 SalI-BlpI chimeras
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Mapping of determinants of infectivity in gp41 using MfeI-BlpI and SalI-BlpI chimeras
I first evaluated the infectivity of chimeric envelopes where the entire gp41
sequences of B33 or LN40 had been exchanged. For LN40/B33wt MfeI-BlpI, infectivity
was restored, but was still about 10-fold lower than B33wt (Fig.5.5a). I also observed an
approximately 3-fold reduction in infectivity in the B33/LN40wt MfeI-BlpI chimera,
compared to B33wt (Fig. 5.5a)
Next, I evaluated chimeras in which the C-terminal end of the gp41 cytoplasmic
domain (between the SalI and BlpI site) had been exchanged. A restoration of infectivity
was observed for LN40/B33wt SalI-BlpI, although infectivity was about 6-fold lower
than LN40/B33wt MfeI-BlpI, and about 16-fold lower than B33wt (Fig. 5.5b). There was
also a reduction in infectivity in the B33/LN40wt SalI-BlpI chimera, compared to B33wt
(Fig. 5.5b). This reduction was similar to the reduction seen for the B33/LN40wt MfeI-
BlpI chimera. These results confirm that gp41 plays an important role in LN40
infectivity.
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Fig. 5.5 Ratio of ffu:RT of B33wt, LN40wt, and B33/LN40 chimeras. a) MfeI-BlpI chimeras, b) SalI-BlpI
chimeras. See Fig.5.2 and 5.4 legend for more detail.
a)
b)
Ra
tio
 ff
u: 
RT 0.1
1
10
100
B33wt LN40wt B33/LN40wt MfeI-
BlpI
LN40/B33wt MfeI-
BlpI
0.1
1
10
100
B33wt LN40wt B33/LN40wt SalI-
BlpI
LN40/B33wt SalI-
BlpI
85
The palmitoylation site at position 764
There is a conserved palmitoylation site at position 764 in gp41 that is responsible
for targeting envelope to lipid rafts in the host cell plasma membrane [213][23][287]. The
residue at this position is usually a cysteine, but can also be an amino acid with a bulky
hydrophobic side chain for the virus to retain infectivity. In B33wt, position 764 is the
conserved cysteine, whereas in LN40wt this residue is a phenylalanine. To determine if
this palmitoylation site plays a role in LN40’s reduced infectivity, the phenylalanine (F)
in LN40 was substituted with a cysteine (C). We found that changing the F to a C did not
increase the infectivity of LN40 (Fig. 5.6).
The gag binding site at positions 787 and 788
Two arginines in positions 787 and 788 in gp41 lie within a region of gp41
previously implicated in binding Pr55gag [24][127][188]. B33wt has these two arginines.
In LN40, these residues are substituted by a histidine and a serine at 787 and 788,
respectively.
To determine if these residues were responsible for the difference in infectivity
between LN40 and B33, several versions of LN40 and B33 with different mutations in
these sites were constructed. These sites were also mutated in two of the chimeras made
previously, LN40/B33wt MfeI-BlpI and LN40/B33wt SalI-BlpI (Fig. 5.4b and c).
I observed a slight reduction in infectivity when I substituted HS for RR in B33,
compared to B33wt (Fig. 5.7a). The HS present in the two chimeras had some effect on
infectivity. LN40/B33 HS MfeI-BlpI showed a 3-fold reduction in infectivity compared
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to LN40/B33wt MfeI-BlpI (Fig. 5.7a). LN40/B33 HS SalI-BlpI showed a very slight
reduction compared to LN40/B33wt SalI-BlpI (Fig. 5.7a).
Specific mutations were made in the palmitoylation site at position 764 and in the
RR/HS residues at positions 787 and 788. For LN40, changing the F-HS to C-RR resulted
in a 4-fold increase in infectivity compared to LN40wt (Fig. 5.7b). However, other
combinations of residues, including LN40 F-RS, F-HR, C-RS, and C-HR had little
impact on infectivity (Fig. 5.7b). These results indicate that the HS is detrimental to
LN40 infectivity but has less effect on B33 infectivity.
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Fig. 5.6 Ratio of ffu:RT: The effect of the palmitoylation site at position 764. B33 wt, LN40 wt, and
LN40 C. See Fig. 5.4 legend for more detail.
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Fig. 5.7 Ratio of ffu:RT:  The effects of the gag binding site at positions 787 and 788. a) The effects in
chimeras. b) The effects as point mutations.  See Fig. 5.4 legend for more detail.
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TIP47 binding region at positions 793 and 796
TIP47 is a cellular protein that has been reported to connect gag and envelope
[166]. TIP47 also recruits Rab9 GTPase, which directs endosome-to-Golgi vesicular
transport [26][45]. The TIP47 binding motif at positions 802 and 803 is a tyrosine
followed by a tryptophan (YW). This motif is preserved in LN40; however there are two
changes just upstream of this site at 793 and 796, which may influence the function of the
YW motif. In B33, these amino acids are a phenylalanine (F) and a valine (V), while in
LN40, there are leucines (L) in both sites.
These sites were changed to FV in both LN40wt and LN40 C-RR. I found that
changing these sites from two leucines to FV did not increase the infectivity of LN40 in
either the wt or C-RR forms (Fig. 5.8).
Dileucine motif at position 855 and 856
There is a dileucine motif at the end of the cytoplasmic domain of gp41 that is
important for recruiting AP-1 found in clathrin-coated pits [286]. This dileucine motif is
not present in LN40wt, but is present in B33wt. I restored the dileucine motif in LN40wt,
as well as in LN40 C-RR. Restoration of the dileucine motif in LN40wt increases
infectivity slightly. However restoration of the dileucine motif in LN40 C-RR conferred a
24-fold increase in infectivity compared to LN40wt (Fig. 5.9).
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Fig. 5.8 Ratio of ffu:RT:  The TIP47 binding region at positions 793 and 796. See Fig. 5.4 legend for
more detail.
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Fig. 5.9 Ratio of ffu:RT:  The dileucine motif at position 856. See Fig. 5.4 legend for more detail.
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Motifs between the MfeI and SalI sites
Above, I have described a number of changes made in LN40wt. All of these
changes were downstream from the Kennedy/ Dimmock loop, between the SalI and BlpI
sites in the C-terminal of gp41. Data from the LN40/B33 MfeI-BlpI chimera (carrying the
entire B33 gp41), and the LN40/B33wt SalI-BlpI chimera (carrying only the cytoplasmic
domain beyond the Kennedy/ Dimmock loop) indicate that there are possibly
determinants between the MfeI and SalI sites (Fig.5.7a). To explore the differences
between B33wt and LN40wt upstream of the SalI site, I substituted amino acids in LN40
for those in B33wt. These included a tyrosine-to-leucine change (position 625), a
threonine-to-asparagine change (position 649), an asparagine-to-lysine change (position
669), lysine-to-arginine and methionine-to-isoleucine changes (positions 687 and 690,
respectively), and a threonine to valine change (position 702). These substitutions were
all constructed separately, with the exception of the lysine-to-arginine and methionine-to-
isoleucine changes in the transmembrane domain. Because these were only two amino
acids apart, the substitutions were made together. All of these substitutions were made in
LN40wt and LN40 C-RRL856.
These substitutions had no effect on LN40 infectivity in either the LN40wt or
LN40 C-RRL856 backgrounds, and may even adversely affect infectivity (Fig. 5.10)
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Fig.5.10 Ratio of ffu:RT: Motifs between the MfeI and SalI sites. a)Point mutations in LN40wt. b) Point
mutations in LN40 C-RRL856, with LN40/B33wt MfeI-BlpI for comparison. See Fig. 5.4 legend for
more detail.
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Assembly of envelope onto virus particles
Previous data suggested that LN40wt virus particles had less envelope on them
than B33wt virus particles as detected by Western blot [24]. I first examined properties of
envelope+ pseudovirions concentrated by centrifugation. Virus particles in envelope+
pseudotype stocks were pelleted, and resuspended in DMEM. The titer (ffu/mL), RT
activity (pg/mL, a measure of physical virus particles), and gp120 (ng/mL) content of the
virus particles were estimated (see Materials and Methods). Using this method, I found
that B33wt particles have about twice as much gp120 than LN40wt particles (Table 5.2).
I attempted to confirm this data, as well as the previous data, by evaluating
envelope concentration of pelleted virus particles by Western blot using a monoclonal
antibody to gp41, and was unable to do so. These Western blots were inconclusive, and
showed similar amounts of envelope on both B33wt and LN40wt virus particles (Fig.
5.11a). When these envelopes were expressed alone without other viral proteins,
envelope was still detected after filtration and centrifugation (Fig. 5.11b). There is “leak
through” of envelope not on virions in our preparations. This leak through makes
interpretation of the Western blots problematic. It also suggests that the data in Table 5.2
do not accurately represent envelope content on virions.
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Table 5.2 Envelope content on B33wt and LN40wt virus particles
Virus: Titer
(ffu/mL)
RT (pg/mL) gp120
(ng/mL)
Ratio
gp120:RT
Percentage
gp120:RT ratio
(of B33wt)
B33wt 1.32x106 255858 46.1625 2X10-4 100
LN40wt 2.6x104 253265 24.2525 9.6x10-5 53
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Fig. 5.11 Western blots for gp41 and p24. a) Representative Western blot of virus particles; b)
Representative Western blot of virus particles and envelope only samples. Supernatants from
transfections werespun at 3000rpm, filtered through .45um filters, then spun at 22,000rpm for 2 hours
at 40C. Pellets were resuspended in 20uL Laemmli buffer, and loaded onto an SDS-PAGE gel. Blots
were probed for gp41 and p24
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 Discussion
Here, I have identified determinants in the gp41 of LN40 envelope that are
responsible for its decreased infectivity compared to B33. The LN40 chimera containing
the entire gp41 of B33, LN40/B33wt MfeI-BlpI, has the greatest increase on LN40
infectivity (Fig. 5.5a). Several of these infectivity determinants are present in sites with
known functions, including the palmitoylation site (position 764; Fig. 5.6), gag-binding
sites (positions 787 and 788; Fig. 5.7), and the dileucine motif at the C-terminus (position
856; Fig. 5.9). The greatest effect on LN40 infectivity is seen when these determinants
contribute together (Fig. 5.10b). Point mutations proximal to the TIP47 binding motif had
no effect on LN40 infectivity (Fig. 5.8). Other point mutations between the MfeI and SalI
sites also had no effect on LN40 infectivity (Fig. 5.10). Experiments to determine if
LN40wt virus particles carried less envelope than B33wt particles were inconclusive due
to problems with protein contamination of non-virion envelope following particle
concentration (Fig. 5.11b).
Data from the MfeI-BlpI and SalI-BlpI chimeras indicated that important
infectivity determinants were in gp41. LN40/B33 chimeras showed an increase in
infectivity, while B33/LN40 chimeras showed slight decreases in infectivity (Fig. 5.5).
These results led me to investigate motifs in gp41, specifically in the cytoplasmic
domain. The palmitoylation residue at position 764, usually a conserved cysteine, is a
phenylalanine in LN40. Reportedly, this is still acceptable, as envelopes with amino acids
with bulky hydrophobic side chains in this position also retain infectivity [23][213][287].
Changing the phenylalanine to a cysteine in LN40 unsurprisingly had little impact.
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The residues at positions 787 and 788 in gp41 were previously reported to be
important for binding Pr55gag [213]. These residues are usually two arginines. In LN40,
they are a histidine and a serine. Changing these residues to two arginines, along with
restoration of the cysteine at the palmitoylation site, result in a modest increase in
infectivity. Changing these two arginines to histidine and serine in B33 has no effect on
infectivity. Replacing these residues with histidine and serine in the LN40/B33 chimeras
also has little effect on infectivity. This suggests that the effect of these Pr55gag binding
residues is context dependent.
The dileucine motif at the C-terminus recruits AP-1 in clathrin-coated pits [286].
Restoration of this motif results in an increase in infectivity, especially in LN40 C-RR.
The largest increase in infectivity is seen in the quadruple mutant, LN40 C-RR L856,
when L856 is combined with C-RR. It is clear that a combination of these four residues
make a major contribution to the low infectivity of LN40.
The simplest explanation for the differences in infectivity between LN40 and B33
is that LN40 envelope has an assembly defect as previously reported; however this could
not be confirmed. If B33 and LN40 carry similar levels envelope on virions, and are both
fusogenic, then the gp41 determinants identified here may conceivably contribute to an
uncoating, post-fusion stage of entry.
When the LN40 gp41 was introduced in B33, there was only a marginal effect on
infection, indicating that these gp41 determinants are context dependent. In addition, B33
gp41 failed to rescue LN40 infectivity to the level of B33, suggesting that determinants in
gp120 also contribute. LN40 and B33 gp120s were reported to confer different levels of
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infection in primary macrophages [201]. The capacity to use low CD4 may make B33
gp120 more efficient for fusion and overcome gp41 defects that either limit envelope
incorporation onto virions, or adversely affect entry events.
In conclusion, replacing the entire gp41 of LN40 with that of B33 results in an
increase in infectivity. Determinants within gp41 are part of the explanation for the
decreased infectivity of LN40; however, no combination of determinants completely
restores LN40 infectivity. It is likely that differences in gp120 between LN40 and B33
are the reasons for low LN40 infectivity. These differences may lie in the CD4 binding
site, V3 coreceptor binding regions, or in other undefined regions associated with the
ability to use low levels of CD4 for infection, like on macrophages. Mapping these
determinants in gp120 may help elucidate what regions are responsible for macrophage-
tropism.
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General Discussion
In this thesis, I present data from three projects. These projects focused on three
very different aspects of HIV-1 biology, but they ultimately had one common goal: the
understanding of HIV-1 pathogenesis in macrophages. Infected macrophages play an
important role during in vivo HIV infection; however some aspects of the relationship
between HIV and macrophages are still undefined.
The first project I presented in this thesis explored the potential for vpu-
independent envelopes to evolve in vivo. I looked at two envelopes, AD8 and YU-2,
which had previously been reported to be vpu-independent [227] [163]. NL4.3/AD8 vpu-
and NL4.3/YU-2 vpu- both were released to lower levels from macrophages than their
vpu+ counterparts (Fig. 3.3). Full length AD8 vpu- and full length YU-2 vpu- were also
released to lower levels from macrophages compared to their vpu+ counterparts (Fig. 3.2)
These data show that neither the AD8 nor the YU-2 envelope were able to compensate
for the lack of functional vpu, and are therefore not vpu-independent, contrary to these
previous reports. In the discussion section of Chapter III, I went into detail about why my
results did not agree with previously published reports. Here, I will discuss the
implications of my results, speculate on their importance and propose future work for this
project.
As a protein with ion channel characteristics important for its virus release
function, vpu is an attractive target for ion channel blockers, such as amiloride
derivatives [86]. Since HIV-1 can easily evolve to escape other drugs, such as protease
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and reverse transcriptase inhibitors, it is possible that HIV-1 could evolve to escape
amiloride derivatives as well, if they become widely used. In this thesis, I present data
that show how absolutely essential vpu is to sustaining infection in macrophages.
Without functional vpu, viruses are unable to maintain high levels of virus output. It is
likely that treating patients with amiloride derivatives may vastly decrease the number of
macrophages infected, and the amount of virus infected macrophages are able to release.
Envelopes are not likely to evolve the ability to compensate for the lack of functional
vpu. Envelope is dependent upon functional vpu in two ways. One, envelope needs
functional vpu in order to eliminate CD4:envelope complexes from the endoplasmic
reticulum. Two, envelope, and the virus as a whole, require functional vpu for virus
particles to be released from host cell membranes.  It would probably require a significant
number of changes in envelope to compensate for the lack of functional vpu, caused by
the presence of amiloride derivatives. This means that these drugs may be a valid
alternative for antiretroviral therapy. Future work may include passaging viruses through
macrophages in the presence of amiloride derivatives to check that the envelopes do not
evolve to compensate for the lack of functional vpu.
This project initially began with a very limited survey of vpu sequences derived
from a variety of patient tissues. The goal was to find patients with mutated vpu genes,
and study the envelopes associated with those mutated vpu genes. This sequence survey
was discontinued when the AD8 envelope was found not to be vpu-independent. I chose
to focus on the effects of non-functional vpu genes on HIV-1 infection of macrophages,
and try to resolve why the AD8 envelope was not vpu-independent. It may be useful to
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resume this survey, since an exhaustive search for vpu-start codon mutations has never
been done.
Two vpu start codon mutations from patient material have been reported, both
from the brain tissue of infected patients [163] [255]. It may be especially useful to look
specifically at brain tissue, or specific cell types in brain tissue using laser capture
microscopy. If macrophages are the main route to the brain, vpu start codon mutations
present there implies either a) a vpu- virus infected a macrophage, and that macrophage
subsequently entered the brain, or b) that vpu start codon mutations can evolve in brain
tissue in vivo, when sequestered from immune pressures. Vpu- viruses are known to
express more envelope than vpu+ viruses [227] [245]. The presence of more envelope
may lead to more syncytia formation, and therefore more neuronal damage. Vpu- viruses’
presence in the brain may lead to increased HIV-associated dementia.
The second project I presented in this thesis explored the relationship between the
presence of neutralizing antibodies and macrophage-tropic envelopes over the course of
infection. I assessed the macrophage-tropism of envelopes derived from different time
points from four patients, knowing their neutralizing antibody profiles. All patients
developed autologous neutralizing antibodies by 3 months post infection; however, only
three of the four patients developed heterologous neutralizing antibodies (Patients MM1,
4, and 23; Figs. 4.1b, 4.2b, 4.3b, 4.4b). Patients MM1, MM4, and MM8 developed
macrophage-tropic envelopes (Figs. 4.1a, 4.2a, 4.3a). Patient MM23 did not (Fig. 4.4a).
Of the macrophage-tropic envelopes presented here, only two were also sensitive to the
human monoclonal antibody b12. These data show that macrophage-tropism varies
102
substantially over the course of infection, and the presence of autologous neutralizing
antibodies did not predict the absence of macrophage-tropic envelopes. Also, sensitivity
to b12 neutralization did not correlate with macrophage-tropism, as has been previously
reported with other envelopes derived from patient material [202].
HIV-1 is not unique in its ability to infect macrophages. The ability to infect, and
replicate in, non-dividing cells is a characteristic of lentiviruses in general. HIV-1 has
expanded its tropism to also infect CD4+ T cells [266]. Infection of CD4+ T cells is
convenient and effective for HIV, yet HIV still retains the ability to infect macrophages.
From an evolutionary point of view, retaining the ability to infect macrophages must give
HIV an advantage. This advantage is likely linked to the fact that macrophages tolerate
HIV-1 infection, exhibiting no cytopathic effects [266]. Macrophages provide a great
reservoir for HIV-1, especially in later stages of infection, when the CD4+ T cells have
declined drastically [133]. In the patients presented in this thesis, macrophage-tropic
envelopes appeared during the asymptomatic stages of infection, when CD4+ T cell
counts were still above 200 cells/µl. This suggests that the acquisition of macrophage-
tropism occurs well before the onset of CD4+ T cell decline, and is retained over time.
The patients examined here were discharged from the study when they
commenced HAART. Because of this, there is no data from these patients from the
symptomatic stages of infection. It would be interesting to examine envelopes from these
patients in the late stages to see if their macrophage-tropism is retained, or if the number
of macrophage-tropic envelopes present increases. It would also be interesting to see of
the commencement of HAART affects the macrophage-tropism of these patients’
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envelopes. There is evidence as well that suggests the compartmentalization of
macrophage-tropic envelopes (macrophage-tropic envelopes are more prevalent in brain
than in blood) is less obvious after long-term antiretroviral therapy (D. Gabuzda, P.
Clapham, personal communications). These patients would be good to examine to see if
this breakdown of compartmentalization does exist.
The patients presented here all developed strong autologous neutralizing antibody
responses. However, they did not develop strong heterologous neutralizing antibody
responses. These patients’ antibody responses were very specific to the envelopes that
evolved during their infections, but their responses were not broadly neutralizing. This is
worrisome, since a vast majority of vaccine strategies developed against HIV depend on
creating a broadly neutralizing antibody response. This may not be possible, and more
work should be done to develop vaccines that utilize the cell-mediated response as well
as the antibody response.
In two patients, macrophage-tropic envelopes appeared before the detection of
autologous neutralizing antibodies, and these patients retained this macrophage-tropism.
The third patient had macrophage-tropic envelopes after the appearance of autologous
neutralizing antibodies. If macrophage-tropic envelopes are more sensitive to neutralizing
antibodies, these envelopes should disappear after the onset of the antibody response.
This is not the case in the patients presented here. Therefore, the antibody response does
not drive viruses away from macrophage-tropism. The driving force behind macrophage-
tropism is more likely the slow decline of alternative target cells as disease progresses.
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Macrophage-tropic envelopes tend to be sensitive to the human monoclonal
antibody b12. The b12 antibody is unique. It has an unusual structure for an antibody. It
is an IgG antibody with an extended hypervariable loop that can fit into gp120, unlike
other IgG antibodies [211, 217]. b12 binds to an area proximal to the CD4 binding site on
gp120. The CD4 binding site on gp120 is tucked up inside the trimer before contact with
CD4 [152]. Upon binding, the CD4 binding site becomes exposed, and a series of
conformational changes occur in gp120 and gp41 that result in the fusion of the viral and
host cell membranes. When the CD4 binding site is tucked away in the native gp120
conformation, the virus typically needs high levels of CD4 in order to infect cells.
However, some envelopes have a more exposed CD4 binding site, which is thought to
help them use lower levels of CD4, like on macrophages. Macrophage-tropic envelopes
probably have a more exposed CD4 binding site than non-macrophage-tropic envelopes.
Since b12 binds a region proximal to the CD4 binding site, envelopes that are
macrophage-tropic tend to be more sensitive to b12 neutralization because their CD4
binding site is more exposed.
Of the macrophage-tropic envelopes presented in this thesis, only two are also
sensitive to b12 neutralization (4.10.3 and 8.8.3). This suggests that these two envelopes
have more exposed CD4 biding sites, but that the other macrophage-tropic envelopes do
not. The CD4 binding site is an important determinant of macrophage-tropism, but it is
not the only determinant. The V3 loop, which carries determinants for coreceptor usage,
and the V4 loop, which has an N-linked glycosylation site important for macrophage
infection, also provide determinants of macrophage-tropism [125] [132] [208][79]. There
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are likely many other determinants of macrophage-tropism, in gp120, and possibly gp41,
that need to be mapped.
The envelopes from these four patients may provide an excellent way to map
these additional determinants. Chimeric gp120 sequences could be created using
envelopes from the same point in which one or more envelopes are macrophage-tropic,
and one or more envelopes are not macrophage-tropic. Sections of gp120 could be
swapped back and forth between these envelopes to find what sections of gp120 can
make a non-macrophage-tropic envelope able to infect macrophages.
Other work may include using anti-CD4 antibodies to elucidate the structure of
these macrophage-tropic envelopes. These envelopes have not been tested for their
sensitivity to anti-CD4 antibodies, which may be useful. The structures of the b12
sensitive macrophage-tropic envelopes versus the b12 resistant macrophage-tropic
envelopes are possibly different. This work may suggest what changes have occurred in
these envelopes’ CD4 binding sites.
The third project I presented in this thesis explored possible determinants in gp41
responsible for infectivity. Two envelopes, B33 and LN40, are from two separate tissues
from one patient; they have very different characteristics of infectivity on cells expressing
high levels of CD4 (Fig. 5.2a). When the gp41 of LN40 is replaced with that of B33,
there is a restoration in infectivity (Fig. 5.5a). Changes in the palmitoylation site (at
position 765), Pr55gag binding sites (at positions 787 and 788), and the dileucine motif at
the C-terminal (at position 852) increase the infectivity of LN40, but these changes do
not completely restore infectivity (Fig 5.9). Virus particle isolation and Western blots to
106
determine the amount of envelope on LN40wt virus particles were inconclusive due to
non-virion particle contamination (Fig. 5.11; Appendix B).
While the combination of determinants described here increase the infectivity of
LN40 slightly, it is unknown if these determinants are universal. The amino acids in these
determinants in LN40 could be placed in well-characterized molecular clones, such as
NL4.3 and AD8, to assess whether they decrease infectivity. It is possible that these
amino acids are context dependent, in that they only decrease the infectivity of the LN40
envelope.
This project began with the observation that replacing the gp41 of LN40 with that
of B33 restored infectivity to LN40 envelope. gp41 has many attractive domain that may
impact infectivity. Therefore, I began trying to map these determinants of infectivity. As I
created new chimeras and point mutations, I found that no combination of determinants
completely restored infectivity to LN40, even when its entire gp41 is replaced. There are
likely additional determinants in gp120 that impact LN40’s infectivity.
These determinants may be in LN40 envelope’s inability to use low levels of
CD4. LN40 is not macrophage-tropic, while B33 is macrophage-tropic. The B33 gp120
may have a more exposed CD4 binding site than LN40 gp120. LN40 is resistant to b12
neutralization, which is consistent with previous reports that non-macrophage-tropic
envelopes are more resistant to b12 neutralization because their CD4 binding sites are
hidden [202].
As was mentioned above, there are still undefined determinants of macrophage-
tropism outside of the CD4 binding site. The B33 and LN40 envelopes provide an
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opportunity to map these determinants because they are closely related. Creating
chimeras using gp120 sequences from B33 and LN40 may be a way of mapping these
determinants.
A key question in this project is how much envelope is present on B33 and Ln40
pseudotyped virus particles. Previous work in my lab indicated that there was less
envelope on LN40 particles compared to B33 particles [24]. This provided a fairly simple
explanation: LN40 gp41 had an assembly defect responsible for this envelope’s
decreased infectivity. Unfortunately, I was unable to repeat this previous result. There
seems to be non-virion protein contamination in my preparations, which makes
interpreting the amount of envelope on LN40 virus particles difficult. Using Optiprep
gradients may provide the best solution for eliminating this non-virion contamination. I
tried using Optiprep gradients, but there was not enough antigen in the gradient to detect
on the Western Blot. Increasing the amount of antigen loaded onto the gradient before
centrifugation would solve this issue. The immunoprecipitation protocol used to obtain
virus particles from the steps in the gradient may also need to be optimized to extract the
maximum amount of antigen. However, radioactively labeling the antigen in the gradient
would allow me to skip the immunoprecipitation protocol, and would be more direct.
Once the virus particle isolation protocol has been optimized, the LN40 chimeric and
point mutation constructs can also be assessed for the amount of envelope assembled
onto particles. It may be interesting to find if one of the constructs improves the assembly
of envelope onto LN40 virus particles.
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Since the experiments for this project were done using pseudotyped virus
particles, is also possible that the differences in infectivity between B33 and LN40 may
be due to problems in LN40’s ability to NL4.3 gag. LN40 may be able to bind to its own
gag better. Unfortunately, it would be extremely difficult to derive the gag that came
from the same provirus as LN40. However, gag sequences from the same autopsy lymph
node tissue could be amplified, and LN40 envelope could be pseudotyped onto these gag
sequences. Another option is immunoprecipitation and Western blotting of LN40
pseudotyped onto NL4.3 particles could clarify if this envelope properly binds to NL4.3
gag.
The B33 and LN40 envelopes provide an interesting snapshot of envelopes at the
end stages of AIDS. Both envelopes were derived from tissues at autopsy of an HIV+
patient that died of complications of AIDS [201]. B33 was derived from brain tissue, and
is very macrophage-tropic. This suggests that at some point, this virus infected a
macrophage in the blood, and was carried to the brain.  LN40, from the lymph node
tissue, is not macrophage-tropic. This envelope was restricted to T cells, and the blood.
These two envelopes provide a unique case of macrophage-tropism becoming useful at
one point in infection, and therefore retained. Developing macrophage-tropism expanded
the repertoire of cells the viruses in this patient could infect.
HIV has impacted the entire population of the planet Earth. This virus has gained
a fantastic foothold into humans. It has become uniquely adapted to its host, exploiting a
necessary cell type of the immune system: macrophages. Why and how HIV infects
macrophages are complex questions.
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HIV uses macrophages as a reservoir over the course of infection. This allows
HIV to persist, without interference from the rest of the immune system. If we can find a
way to prevent HIV infection of macrophages, we may have a chance at beating AIDS.
Macrophages may be some of the first cells infected. If this initial event could be
prevented, the person may not become infected at all. However, this requires
understanding the initial events of HIV infection of macrophages, including the
characteristics of viruses that successfully infect macrophages, and what could happen if
treatments targeting genes important for macrophage infection are used. The key to
preventing and treating disease is understanding it at its most basic level. The basic
understanding of HIV infection of macrophages is still needed.
In this thesis, I attempted to contribute to this understanding. There is still a great
deal to be explored, but I hope the work I presented here provides some insight. Thank
you, and goodnight.
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Appendix A: Primary data for Chapter IV
The following Appendix contains primary data from one set of infections for
Patients MM1, MM4, MM8, MM23, along with control viruses. The following tables
have the titer (in ffu/mL) from TZM-bl, RC49 and macrophage infections, in duplicate,
the average titers from these infections, and the standard deviation.
These tables also have the percent infectivity for each virus on TZM-bl cells,
RC49 cells, and macrophages. The percent infectivity was calculated by dividing the
average titer on the cell type of interest by the average titer on TZM-bl cells, and
multiplying by 100.
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Appendix B: Western blots for Chapter V
The following Appendix contains pictures of Western blots done to determine the
amount of envelope on B33wt and LN40wt pseudovirus particles. When I was unable to
repeat the data previously published [24], I made several changes to the original
ultracentrifugation protocol (see Materials and Methods). The following blots are
representative of the different changes I made in the attempt to repeat the original data, as
well as eliminate the protein leak through problem mentioned in Chapter V (Fig. 5.11).
Descriptions of the changes I made to the protocol are detailed in the figure legends. Each
picture here, and in Fig. 5.11, represents many attempts.
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Fig. B1 Representative Western blots. Protocol changes: supernatants spun at 5000rpm
(instead of 3000rpm), filtered through .22um filter (instead of .45um filter), then layered onto
2.5% sucrose cushion. Samples were ultracentrifugated at 22000 rpm for 2 hours at 4oC. . On
some occasions, the protein leak-through was lessened (a), other times not at all (b).
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Fig. B2 use of Optiprep. My first attempts at using an Optiprep gradient (11 steps,
in 1.2% increments, from 6% to 18%; Dettenhofer & Yu, J.Virol, 1999) were
unsuccessful (not shown). Next, I tried using Optiprep cushoins. Supernatants
were spun at 3000rpm, then layered onto Optiprep cushions as indicated. Pellets
were resuspended, then run on SDS-PAGE gel, then blotted. These optiprep
cushoins do not solve the problem of protein leak-through. They also decrease the
amount of antigen, making interpreting the blots difficult.
B3
3 w
t 1
5.6
%
B3
3 w
t 1
2%
B3
3 w
t 9
.6%
B3
3 w
t e
nv
 on
ly 
15
.6%
B3
3 w
t e
nv
 on
ly 
12
%
B3
3 w
t e
nv
 on
ly 
9.6
%
gp160
gp41
p24
116
Bibliography
1. Aasa-Chapman, M. M., A. Hayman, P. Newton, et al. 2004. Development of the
antibody response in acute HIV-1 infection. AIDS 18:371-381.
2. Abada, P., B. Noble, and P. M. Cannon. 2005. Functional domains within the
human immunodeficiency virus type 2 envelope protein required to enhance virus
production. J Virol 79:3627-3638.
3. Adachi, A., M. Miyaura, A. Sakurai, et al. 2001. Growth characteristics of SHIV
without the vpu gene. Int J Mol Med 8:641-644.
4. Adamson, C. S., S. D. Ablan, I. Boeras, et al. 2006. In vitro resistance to the
human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J
Virol 80:10957-10971.
5. Albert, J., B. Abrahamsson, K. Nagy, et al. 1990. Rapid development of isolate-
specific neutralizing antibodies after primary HIV-1 infection and consequent
emergence of virus variants which resist neutralization by autologous sera. AIDS
4:107-112.
6. Allan, J. S., J. E. Coligan, F. Barin, et al. 1985. Major glycoprotein antigens that
induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091-
1094.
7. Amarasinghe, G. K., R. N. De Guzman, R. B. Turner, et al. 2000. NMR
structure of the HIV-1 nucleocapsid protein bound to stem-loop SL2 of the psi-
RNA packaging signal. Implications for genome recognition. J. Mol. Biol. 301:491-
511.
8. Amarasinghe, G. K., R. N. De Guzman, R. B. Turner, and M. F. Summers.
2000. NMR structure of stem-loop SL2 of the HIV-1 psi RNA packaging signal
reveals a novel A-U-A base-triple platform. J. Mol. Biol. 299:145-156.
9. Anderson, J. L., A. T. Johnson, J. L. Howard, and D. F. Purcell. 2007. Both
linear and discontinuous ribosome scanning are used for translation initiation from
bicistronic human immunodeficiency virus type 1 env mRNAs. J Virol 81:4664-
4676.
10. Ascher, M. S., and H. W. Sheppard. 1988. AIDS as immune system activation: a
model for pathogenesis. Clin Exp Immunol 73:165-167.
11. Bailes, E., F. Gao, F. Bibollet-Ruche, et al. 2003. Hybrid origin of SIV in
chimpanzees. Science 300:1713.
12. Balliet, J. W., D. L. Kolson, G. Eiger, et al. 1994. Distinct effects in primary
macrophages and lymphocytes of the human immunodeficiency virus type 1
accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.
Virology 200:623-631.
13. Baltimore, D. 1970. RNA-dependent DNA polymerase in virions of RNA tumour
viruses. Nature 226:1209-1211.
14. Bannert, N., D. Schenten, S. Craig, and J. Sodroski. 2000. The level of CD4
expression limits infection of primary rhesus monkey macrophages by a T-tropic
117
simian immunodeficiency virus and macrophagetropic human immunodeficiency
viruses. J Virol 74:10984-10993.
15. Barlow, K. L., A. O. Ajao, and J. P. Clewley. 2003. Characterization of a novel
simian immunodeficiency virus (SIVmonNG1) genome sequence from a mona
monkey (Cercopithecus mona). J Virol 77:6879-6888.
16. Barre-Sinoussi, F., J. C. Chermann, F. Rey, et al. 1983. Isolation of a T-
lymphotropic retrovirus from a patient at risk for acquired immune deficiency
syndrome (AIDS). Science 220:868-871.
17. Barre-Sinoussi, F., J. C. Chermann, F. Rey, et al. 1983. Isolation of a T-
lymphotropic retrovirus from a patient at risk for acquired immune deficiency
syndrome (AIDS). Science 220:868-871.
18. Bartel, D. P., M. L. Zapp, M. R. Green, and J. W. Szostak. 1991. HIV-1 Rev
regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell
67:529-536.
19. Beerens, N., F. Groot, and B. Berkhout. 2001. Initiation of HIV-1 reverse
transcription is regulated by a primer activation signal. J. Biol. Chem. 276:31247-
31256.
20. Bell, I., C. Ashman, J. Maughan, et al. 1998. Association of simian
immunodeficiency virus Nef with the T-cell receptor (TCR) zeta chain leads to
TCR down-modulation. J. Gen. Virol. 79:2717-2727.
21. Berlioz-Torrent, C., B. L. Shacklett, L. Erdtmann, et al. 1999. Interactions of
the cytoplasmic domains of human and simian retroviral transmembrane proteins
with components of the clathrin adaptor complexes modulate intracellular and cell
surface expression of envelope glycoproteins. J Virol 73:1350-1361.
22. Besnard-Guerin, C., N. Belaidouni, I. Lassot, et al. 2004. HIV-1 Vpu sequesters
beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes
the accumulation of beta-catenin and other SCFbetaTrCP substrates. J. Biol. Chem.
279:788-795.
23. Bhattacharya, J., P. J. Peters, and P. R. Clapham. 2004. Human
immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic
domain cysteines: impact on association with membrane lipid rafts and
incorporation onto budding virus particles. J Virol 78:5500-5506.
24. Bhattacharya, J., A. Repik, and P. R. Clapham. 2006. Gag regulates association
of human immunodeficiency virus type 1 envelope with detergent-resistant
membranes. J Virol 80:5292-5300.
25. Bieniasz, P. D., R. A. Fridell, I. Aramori, et al. 1997. HIV-1-induced cell fusion
is mediated by multiple regions within both the viral envelope and the CCR-5 co-
receptor. EMBO J. 16:2599-2609.
26. Blot, G., K. Janvier, S. Le Panse, R. Benarous, and C. Berlioz-Torrent. 2003.
Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi
network through binding to TIP47 is required for env incorporation into virions and
infectivity. J Virol 77:6931-6945.
118
27. Boge, M., S. Wyss, J. S. Bonifacino, and M. Thali. 1998. A membrane-proximal
tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein
via interaction with the AP-2 clathrin adaptor. J. Biol. Chem. 273:15773-15778.
28. Bohnlein, S., J. Hauber, and B. R. Cullen. 1989. Identification of a U5-specific
sequence required for efficient polyadenylation within the human
immunodeficiency virus long terminal repeat. J Virol 63:421-424.
29. Bour, S., R. Geleziunas, and M. A. Wainberg. 1995. The human
immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in
promotion of HIV-1 infection. Microbiol. Rev. 59:63-93.
30. Bour, S., U. Schubert, and K. Strebel. 1995. The human immunodeficiency virus
type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4:
implications for the mechanism of degradation. J Virol 69:1510-1520.
31. Bour, S., and K. Strebel. 1996. The human immunodeficiency virus (HIV) type 2
envelope protein is a functional complement to HIV type 1 Vpu that enhances
particle release of heterologous retroviruses. J Virol 70:8285-8300.
32. Bowers, K., A. Pelchen-Matthews, S. Honing, et al. 2000. The simian
immunodeficiency virus envelope glycoprotein contains multiple signals that
regulate its cell surface expression and endocytosis. Traffic 1:661-674.
33. Brenchley, J. M., D. A. Price, and D. C. Douek. 2006. HIV disease: fallout from a
mucosal catastrophe? Nat Immunol 7:235-239.
34. Brenchley, J. M., D. A. Price, T. W. Schacker, et al. 2006. Microbial
translocation is a cause of systemic immune activation in chronic HIV infection.
Nat. Med. 12:1365-1371.
35. Brenchley, J. M., T. W. Schacker, L. E. Ruff, et al. 2004. CD4+ T cell depletion
during all stages of HIV disease occurs predominantly in the gastrointestinal tract.
J. Exp. Med. 200:749-759.
36. Brown, A., S. Moghaddam, T. Kawano, and C. Cheng-Mayer. 2004. Multiple
human immunodeficiency virus type 1 Nef functions contribute to efficient
replication in primary human macrophages. J. Gen. Virol. 85:1463-1469.
37. Brown, P. O., B. Bowerman, H. E. Varmus, and J. M. Bishop. 1989. Retroviral
integration: structure of the initial covalent product and its precursor, and a role for
the viral IN protein. Proc Natl Acad Sci U S A 86:2525-2529.
38. Burton, D. R., R. C. Desrosiers, R. W. Doms, et al. 2004. HIV vaccine design and
the neutralizing antibody problem. Nat Immunol 5:233-236.
39. Caffrey, M., M. Cai, J. Kaufman, et al. 1998. Three-dimensional solution
structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17:4572-4584.
40. Callahan, M. A., M. A. Handley, Y. H. Lee, et al. 1998. Functional interaction of
human immunodeficiency virus type 1 Vpu and Gag with a novel member of the
tetratricopeptide repeat protein family. J Virol 72:5189-5197.
41. Cao, J., L. Bergeron, E. Helseth, et al. 1993. Effects of amino acid changes in the
extracellular domain of the human immunodeficiency virus type 1 gp41 envelope
glycoprotein. J Virol 67:2747-2755.
42. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41
from the HIV envelope glycoprotein. Cell 89:263-273.
119
43. Chanh, T. C., G. R. Dreesman, P. Kanda, et al. 1986. Induction of anti-HIV
neutralizing antibodies by synthetic peptides. EMBO J. 5:3065-3071.
44. Chen, B., E. M. Vogan, H. Gong, et al. 2005. Structure of an unliganded simian
immunodeficiency virus gp120 core. Nature 433:834-841.
45. Chen, L., E. DiGiammarino, X. E. Zhou, et al. 2004. High resolution crystal
structure of human Rab9 GTPase: a novel antiviral drug target. J. Biol. Chem.
279:40204-40208.
46. Cheng-Mayer, C., M. Quiroga, J. W. Tung, D. Dina, and J. A. Levy. 1990. Viral
determinants of human immunodeficiency virus type 1 T-cell or macrophage
tropism, cytopathogenicity, and CD4 antigen modulation. J Virol 64:4390-4398.
47. Cheng-Mayer, C., C. Weiss, D. Seto, and J. A. Levy. 1989. Isolates of human
immunodeficiency virus type 1 from the brain may constitute a special group of the
AIDS virus. Proc Natl Acad Sci U S A 86:8575-8579.
48. Choe, H., M. Farzan, Y. Sun, et al. 1996. The beta-chemokine receptors CCR3
and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
49. Chun, T. W., D. Engel, M. M. Berrey, et al. 1998. Early establishment of a pool
of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc
Natl Acad Sci U S A 95:8869-8873.
50. Clavel, F., D. Guetard, F. Brun-Vezinet, et al. 1986. Isolation of a new human
retrovirus from West African patients with AIDS. Science 233:343-346.
51. Cleveland, S. M., L. McLain, L. Cheung, et al. 2003. A region of the C-terminal
tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1
contains a neutralizing epitope: evidence for its exposure on the surface of the
virion. J. Gen. Virol. 84:591-602.
52. Cohen, E. A., E. F. Terwilliger, Y. Jalinoos, et al. 1990. Identification of HIV-1
vpr product and function. J Acquir Immune Defic Syndr 3:11-18.
53. Cohen, E. A., E. F. Terwilliger, J. G. Sodroski, and W. A. Haseltine. 1988.
Identification of a protein encoded by the vpu gene of HIV-1. Nature 334:532-534.
54. Connor, R. I., and D. D. Ho. 1994. Human immunodeficiency virus type 1
variants with increased replicative capacity develop during the asymptomatic stage
before disease progression. J Virol 68:4400-4408.
55. Conticello, S. G., R. S. Harris, and M. S. Neuberger. 2003. The Vif protein of
HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
Curr. Biol. 13:2009-2013.
56. Corbet, S., M. C. Muller-Trutwin, P. Versmisse, et al. 2000. env sequences of
simian immunodeficiency viruses from chimpanzees in Cameroon are strongly
related to those of human immunodeficiency virus group N from the same
geographic area. J Virol 74:529-534.
57. Cosenza, M. A., M. L. Zhao, Q. Si, and S. C. Lee. 2002. Human brain
parenchymal microglia express CD14 and CD45 and are productively infected by
HIV-1 in HIV-1 encephalitis. Brain Pathol. 12:442-455.
58. Courgnaud, V., B. Abela, X. Pourrut, et al. 2003. Identification of a new simian
immunodeficiency virus lineage with a vpu gene present among different
120
cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J
Virol 77:12523-12534.
59. Courgnaud, V., M. Salemi, X. Pourrut, et al. 2002. Characterization of a novel
simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys
(Cercopithecus nictitans) provides new insights into simian/human
immunodeficiency virus phylogeny. J Virol 76:8298-8309.
60. Crawford, S., and S. P. Goff. 1985. A deletion mutation in the 5' part of the pol
gene of Moloney murine leukemia virus blocks proteolytic processing of the gag
and pol polyproteins. J Virol 53:899-907.
61. Cullen, B. R., J. Hauber, K. Campbell, et al. 1988. Subcellular localization of the
human immunodeficiency virus trans-acting art gene product. J Virol 62:2498-
2501.
62. D.L. Robertson, J. P. A., J.A. Bradac, J.K. Carr, B. Foley, R.K. Funkhouser, F.
Gao, B.H. Hahn, M.L. Kalish, C. Kuiken, G.H. Learn, T. Leitner, F.
McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M.
Sharp,S. Wolinsky, and B. Korber. HIV-1 Nomenclature Proposal:
A Reference Guide to HIV-1 Classification.
63. Dalgleish, A. G., P. C. Beverley, P. R. Clapham, et al. 1984. The CD4 (T4)
antigen is an essential component of the receptor for the AIDS retrovirus. Nature
312:763-767.
64. Daniel, M. D., N. L. Letvin, N. W. King, et al. 1985. Isolation of T-cell tropic
HTLV-III-like retrovirus from macaques. Science 228:1201-1204.
65. Dayton, A. I., J. G. Sodroski, C. A. Rosen, W. C. Goh, and W. A. Haseltine.
1986. The trans-activator gene of the human T cell lymphotropic virus type III is
required for replication. Cell 44:941-947.
66. De Jong, J. J., A. De Ronde, W. Keulen, M. Tersmette, and J. Goudsmit. 1992.
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to
support the syncytium-inducing phenotype: analysis by single amino acid
substitution. J Virol 66:6777-6780.
67. Deacon, N. J., A. Tsykin, A. Solomon, et al. 1995. Genomic structure of an
attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.
Science 270:988-991.
68. Dejucq, N., G. Simmons, and P. R. Clapham. 1999. Expanded tropism of primary
human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined
by the capacity to exploit low concentrations of CCR5. J Virol 73:7842-7847.
69. Dejucq, N., G. Simmons, and P. R. Clapham. 2000. T-cell line adaptation of
human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and
macrophage-tropism. J. Gen. Virol. 81:2899-2904.
70. Delahunty, M. D., I. Rhee, E. O. Freed, and J. S. Bonifacino. 1996. Mutational
analysis of the fusion peptide of the human immunodeficiency virus type 1:
identification of critical glycine residues. Virology 218:94-102.
71. Deng, H., R. Liu, W. Ellmeier, et al. 1996. Identification of a major co-receptor
for primary isolates of HIV-1. Nature 381:661-666.
121
72. Dittmar, M. T., A. McKnight, G. Simmons, et al. 1997. HIV-1 tropism and co-
receptor use. Nature 385(6616):495-496.
73. Doranz, B. J., J. Rucker, Y. Yi, et al. 1996. A dual-tropic primary HIV-1 isolate
that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as
fusion cofactors. Cell 85:1149-1158.
74. Douek, D. C., L. J. Picker, and R. A. Koup. 2003. T cell dynamics in HIV-1
infection. Annu. Rev. Immunol. 21:265-304.
75. Dubay, J. W., S. J. Roberts, B. Brody, and E. Hunter. 1992. Mutations in the
leucine zipper of the human immunodeficiency virus type 1 transmembrane
glycoprotein affect fusion and infectivity. J Virol 66:4748-4756.
76. Dubay, J. W., S. J. Roberts, B. H. Hahn, and E. Hunter. 1992. Truncation of the
human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic
domain blocks virus infectivity. J Virol 66:6616-6625.
77. DuBridge, R. B., P. Tang, H. C. Hsia, et al. 1987. Analysis of mutation in human
cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
78. Dunfee, R. L., E. R. Thomas, P. R. Gorry, et al. 2006. The HIV Env variant
N283 enhances macrophage tropism and is associated with brain infection and
dementia. Proc Natl Acad Sci U S A 103:15160-15165.
79. Dunfee, R. L., E. R. Thomas, J. Wang, et al. 2007. Loss of the N-linked
glycosylation site at position 386 in the HIV envelope V4 region enhances
macrophage tropism and is associated with dementia. Virology 367:222-234.
80. Earl, P. L., and B. Moss. 1993. Mutational analysis of the assembly domain of the
HIV-1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 9:589-594.
81. Earl, P. L., B. Moss, and R. W. Doms. 1991. Folding, interaction with GRP78-
BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope
protein. J Virol 65:2047-2055.
82. Edwards, T. G., T. L. Hoffman, F. Baribaud, et al. 2001. Relationships between
CD4 independence, neutralization sensitivity, and exposure of a CD4-induced
epitope in a human immunodeficiency virus type 1 envelope protein. J Virol
75:5230-5239.
83. Ekstrand, D. H., R. J. Awad, C. F. Kallander, and J. S. Gronowitz. 1996. A
sensitive assay for the quantification of reverse transcriptase activity based on the
use of carrier-bound template and non-radioactive-product detection, with special
reference to human-immunodeficiency-virus isolation. Biotechnol Appl Biochem
23:95-105.
84. Eric O. Freed, M. M. M. 2007. HIVs and Their Replication, In David M. Knipe, P.
M. H. (ed.), Fields Virology, Lippincott Williams & Wilkins, Philadelphia.
85. Evans, D. T., K. C. Tillman, and R. C. Desrosiers. 2002. Envelope glycoprotein
cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab
acceptor. J Virol 76:327-337.
86. Ewart, G. D., K. Mills, G. B. Cox, and P. W. Gage. 2002. Amiloride derivatives
block ion channel activity and enhancement of virus-like particle budding caused by
HIV-1 protein Vpu. Eur Biophys J 31:26-35.
122
87. Ewart, G. D., T. Sutherland, P. W. Gage, and G. B. Cox. 1996. The Vpu protein
of human immunodeficiency virus type 1 forms cation-selective ion channels. J
Virol 70:7108-7115.
88. Farnet, C. M., and F. D. Bushman. 1996. HIV cDNA integration: molecular
biology and inhibitor development. AIDS 10 Suppl A:S3-11.
89. Felber, B. K., M. Hadzopoulou-Cladaras, C. Cladaras, T. Copeland, and G. N.
Pavlakis. 1989. rev protein of human immunodeficiency virus type 1 affects the
stability and transport of the viral mRNA. Proc Natl Acad Sci U S A 86:1495-1499.
90. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry
cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled
receptor. Science 272:872-877.
91. Fischer-Smith, T., S. Croul, A. E. Sverstiuk, et al. 2001. CNS invasion by
CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular
accumulation and reservoir of HIV infection. J. Neurovirol. 7:528-541.
92. Fisher, A. G., M. B. Feinberg, S. F. Josephs, et al. 1986. The trans-activator gene
of HTLV-III is essential for virus replication. Nature 320:367-371.
93. Fouchier, R. A., M. Brouwer, S. M. Broersen, and H. Schuitemaker. 1995.
Simple determination of human immunodeficiency virus type 1 syncytium-inducing
V3 genotype by PCR. J. Clin. Microbiol. 33:906-911.
94. Fouchier, R. A., B. E. Meyer, J. H. Simon, et al. 1998. Interaction of the human
immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol
72:6004-6013.
95. Fox, D. G., P. Balfe, C. P. Palmer, et al. 1997. Length polymorphism within the
second variable region of the human immunodeficiency virus type 1 envelope
glycoprotein affects accessibility of the receptor binding site. J Virol 71:759-765.
96. Freed, E. O., D. J. Myers, and R. Risser. 1990. Characterization of the fusion
domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.
Proc Natl Acad Sci U S A 87:4650-4654.
97. Freed, E. O., J. M. Orenstein, A. J. Buckler-White, and M. A. Martin. 1994.
Single amino acid changes in the human immunodeficiency virus type 1 matrix
protein block virus particle production. J Virol 68:5311-5320.
98. Fu, G. K., G. Grosveld, and D. M. Markovitz. 1997. DEK, an autoantigen
involved in a chromosomal translocation in acute myelogenous leukemia, binds to
the HIV-2 enhancer. Proc Natl Acad Sci U S A 94:1811-1815.
99. Fujita, K., S. Omura, and J. Silver. 1997. Rapid degradation of CD4 in cells
expressing human immunodeficiency virus type 1 Env and Vpu is blocked by
proteasome inhibitors. J. Gen. Virol. 78:619-625.
100. Fujiwara, T., and K. Mizuuchi. 1988. Retroviral DNA integration: structure of an
integration intermediate. Cell 54:497-504.
101. Ganser, B. K., S. Li, V. Y. Klishko, J. T. Finch, and W. I. Sundquist. 1999.
Assembly and analysis of conical models for the HIV-1 core. Science 283:80-83.
102. Gao, F., E. Bailes, D. L. Robertson, et al. 1999. Origin of HIV-1 in the
chimpanzee Pan troglodytes troglodytes. Nature 397:436-441.
123
103. Gao, F., L. Yue, A. T. White, et al. 1992. Human infection by genetically diverse
SIVSM-related HIV-2 in west Africa. Nature 358:495-499.
104. Garcia, J. V., and A. D. Miller. 1991. Serine phosphorylation-independent
downregulation of cell-surface CD4 by nef. Nature 350:508-511.
105. Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, et al. 2001. Tsg101 and the
vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65.
106. Geijtenbeek, T. B., D. S. Kwon, R. Torensma, et al. 2000. DC-SIGN, a dendritic
cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell
100:587-597.
107. Gendelman, H. E., J. M. Orenstein, M. A. Martin, et al. 1988. Efficient isolation
and propagation of human immunodeficiency virus on recombinant colony-
stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441.
108. Gilmartin, G. M., E. S. Fleming, J. Oetjen, and B. R. Graveley. 1995. CPSF
recognition of an HIV-1 mRNA 3'-processing enhancer: multiple sequence contacts
involved in poly(A) site definition. Genes Dev. 9:72-83.
109. Gonzalez-Scarano, F., and J. Martin-Garcia. 2005. The neuropathogenesis of
AIDS. Nat Rev Immunol 5:69-81.
110. Gorry, P. R., G. Bristol, J. A. Zack, et al. 2001. Macrophage tropism of human
immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts
neurotropism independent of coreceptor specificity. J Virol 75:10073-10089.
111. Gorry, P. R., J. Taylor, G. H. Holm, et al. 2002. Increased CCR5 affinity and
reduced CCR5/CD4 dependence of a neurovirulent primary human
immunodeficiency virus type 1 isolate. J Virol 76:6277-6292.
112. Gottlieb, M. S., R. Schroff, H. M. Schanker, et al. 1981. Pneumocystis carinii
pneumonia and mucosal candidiasis in previously healthy homosexual men:
evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305:1425-
1431.
113. Gray, L., J. Sterjovski, M. Churchill, et al. 2005. Uncoupling coreceptor usage of
human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals
biological properties of CCR5-restricted HIV-1 isolates from patients with acquired
immunodeficiency syndrome. Virology 337:384-398.
114. Greenberg, M. E., S. Bronson, M. Lock, et al. 1997. Co-localization of HIV-1
Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-
regulation. EMBO J. 16:6964-6976.
115. Guy, B., M. P. Kieny, Y. Riviere, et al. 1987. HIV F/3' orf encodes a
phosphorylated GTP-binding protein resembling an oncogene product. Nature
330:266-269.
116. Hallenberger, S., V. Bosch, H. Angliker, et al. 1992. Inhibition of furin-mediated
cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358-361.
117. Handley, M. A., S. Paddock, A. Dall, and A. T. Panganiban. 2001. Association
of Vpu-binding protein with microtubules and Vpu-dependent redistribution of
HIV-1 Gag protein. Virology 291:198-207.
118. Harris, R. S., K. N. Bishop, A. M. Sheehy, et al. 2003. DNA deamination
mediates innate immunity to retroviral infection. Cell 113:803-809.
124
119. Haseltine, W. A. 1991. Molecular biology of the human immunodeficiency virus
type 1. FASEB J. 5:2349-2360.
120. Haseltine, W. A., J. Sodroski, R. Patarca, et al. 1984. Structure of 3' terminal
region of type II human T lymphotropic virus: evidence for new coding region.
Science 225:419-421.
121. Heinzinger, N. K., M. I. Bukinsky, S. A. Haggerty, et al. 1994. The Vpr protein
of human immunodeficiency virus type 1 influences nuclear localization of viral
nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 91:7311-7315.
122. Helseth, E., U. Olshevsky, C. Furman, and J. Sodroski. 1991. Human
immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for
association with the gp41 transmembrane glycoprotein. J Virol 65:2119-2123.
123. Hermida-Matsumoto, L., and M. D. Resh. 2000. Localization of human
immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal
imaging. J Virol 74:8670-8679.
124. Hirsch, V. M., R. A. Olmsted, M. Murphey-Corb, R. H. Purcell, and P. R.
Johnson. 1989. An African primate lentivirus (SIVsm) closely related to HIV-2.
Nature 339:389-392.
125. Hoffman, N. G., F. Seillier-Moiseiwitsch, J. Ahn, J. M. Walker, and R.
Swanstrom. 2002. Variability in the human immunodeficiency virus type 1 gp120
Env protein linked to phenotype-associated changes in the V3 loop. J Virol
76:3852-3864.
126. Hoffman, T. L., C. C. LaBranche, W. Zhang, et al. 1999. Stable exposure of the
coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl
Acad Sci U S A 96:6359-6364.
127. Hourioux, C., D. Brand, P. Y. Sizaret, et al. 2000. Identification of the
glycoprotein 41(TM) cytoplasmic tail domains of human immunodeficiency virus
type 1 that interact with Pr55Gag particles. AIDS Res. Hum. Retroviruses 16:1141-
1147.
128. Hout, D. R., L. M. Gomez, E. Pacyniak, et al. 2006. A single amino acid
substitution within the transmembrane domain of the human immunodeficiency
virus type 1 Vpu protein renders simian-human immunodeficiency virus
(SHIV(KU-1bMC33)) susceptible to rimantadine. Virology 348:449-461.
129. Hsu, K., J. Seharaseyon, P. Dong, S. Bour, and E. Marban. 2004. Mutual
functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol Cell 14:259-
267.
130. Huang, M., J. M. Orenstein, M. A. Martin, and E. O. Freed. 1995. p6Gag is
required for particle production from full-length human immunodeficiency virus
type 1 molecular clones expressing protease. J Virol 69:6810-6818.
131. Huang, W., J. Toma, S. Fransen, et al. 2008. Coreceptor Tropism can be
Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of
Human Immunodeficiency Virus Type 1 Envelope Protein. J Virol
132. Hung, C. S., N. Vander Heyden, and L. Ratner. 1999. Analysis of the critical
domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in
CCR5 utilization. J Virol 73:8216-8226.
125
133. Igarashi, T., C. R. Brown, Y. Endo, et al. 2001. Macrophage are the principal
reservoir and sustain high virus loads in rhesus macaques after the depletion of
CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1
chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci
U S A 98:658-663.
134. Iida, S., T. Fukumori, Y. Oshima, et al. 1999. Compatibility of Vpu-like activity
in the four groups of primate immunodeficiency viruses. Virus Genes 18:183-187.
135. Jarry, A., A. Cortez, E. Rene, F. Muzeau, and N. Brousse. 1990. Infected cells
and immune cells in the gastrointestinal tract of AIDS patients. An
immunohistochemical study of 127 cases. Histopathology 16:133-140.
136. (UNAIDS), J. U. N. P. o. H. I. V. A. I. D. S. AIDS epidemic update 2007.
137. Kappes, J. C., C. D. Morrow, S. W. Lee, et al. 1988. Identification of a novel
retroviral gene unique to human immunodeficiency virus type 2 and simian
immunodeficiency virus SIVMAC. J Virol 62:3501-3505.
138. Katoh, I., Y. Yoshinaka, A. Rein, et al. 1985. Murine leukemia virus maturation:
protease region required for conversion from "immature" to "mature" core form and
for virus infectivity. Virology 145:280-292.
139. Kawamura, M., T. Ishizaki, A. Ishimoto, et al. 1994. Growth ability of human
immunodeficiency virus type 1 auxiliary gene mutants in primary blood
macrophage cultures. J. Gen. Virol. 75:2427-2431.
140. Kilby, J. M., S. Hopkins, T. M. Venetta, et al. 1998. Potent suppression of HIV-1
replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
Nat. Med. 4:1302-1307.
141. Kimura, T., M. Nishikawa, and A. Ohyama. 1994. Intracellular membrane traffic
of human immunodeficiency virus type 1 envelope glycoproteins: vpu liberates
Golgi-targeted gp160 from CD4-dependent retention in the endoplasmic reticulum.
J. Biochem. 115:1010-1020.
142. Kino, T., A. Gragerov, A. Valentin, et al. 2005. Vpr protein of human
immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex
formation with Cdc25C: implications for cell cycle arrest. J Virol 79:2780-2787.
143. Kirchhoff, F., T. C. Greenough, D. B. Brettler, J. L. Sullivan, and R. C.
Desrosiers. 1995. Brief report: absence of intact nef sequences in a long-term
survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332:228-232.
144. Klatzmann, D., E. Champagne, S. Chamaret, et al. 1984. T-lymphocyte T4
molecule behaves as the receptor for human retrovirus LAV. Nature 312:767-768.
145. Kliger, Y., A. Aharoni, D. Rapaport, et al. 1997. Fusion peptides derived from
the HIV type 1 glycoprotein 41 associate within phospholipid membranes and
inhibit cell-cell Fusion. Structure-function study. J. Biol. Chem. 272:13496-13505.
146. Koch, M., M. Pancera, P. D. Kwong, et al. 2003. Structure-based, targeted
deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and
antibody recognition. Virology 313:387-400.
147. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992.
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with
an inhibitor. Science 256:1783-1790.
126
148. Kolchinsky, P., E. Kiprilov, and J. Sodroski. 2001. Increased neutralization
sensitivity of CD4-independent human immunodeficiency virus variants. J Virol
75:2041-2050.
149. Kowalski, M., J. Potz, L. Basiripour, et al. 1987. Functional regions of the
envelope glycoprotein of human immunodeficiency virus type 1. Science 237:1351-
1355.
150. Koyanagi, Y., S. Miles, R. T. Mitsuyasu, et al. 1987. Dual infection of the central
nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-
822.
151. Kwon, D. S., G. Gregorio, N. Bitton, W. A. Hendrickson, and D. R. Littman.
2002. DC-SIGN-mediated internalization of HIV is required for trans-enhancement
of T cell infection. Immunity 16:135-144.
152. Kwong, P. D., R. Wyatt, J. Robinson, et al. 1998. Structure of an HIV gp120
envelope glycoprotein in complex with the CD4 receptor and a neutralizing human
antibody. Nature 393:648-659.
153. LaBranche, C. C., T. L. Hoffman, J. Romano, et al. 1999. Determinants of CD4
independence for a human immunodeficiency virus type 1 variant map outside
regions required for coreceptor specificity. J Virol 73:10310-10319.
154. Lalezari, J. P., K. Henry, M. O'Hearn, et al. 2003. Enfuvirtide, an HIV-1 fusion
inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J.
Med. 348:2175-2185.
155. Lecossier, D., F. Bouchonnet, F. Clavel, and A. J. Hance. 2003. Hypermutation
of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
156. Lee, B., M. Sharron, L. J. Montaner, D. Weissman, and R. W. Doms. 1999.
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic
cells, and differentially conditioned monocyte-derived macrophages. Proc Natl
Acad Sci U S A 96:5215-5220.
157. Leiden, J. M., C. Y. Wang, B. Petryniak, et al. 1992. A novel Ets-related
transcription factor, Elf-1, binds to human immunodeficiency virus type 2
regulatory elements that are required for inducible trans activation in T cells. J Virol
66:5890-5897.
158. Lenburg, M. E., and N. R. Landau. 1993. Vpu-induced degradation of CD4:
requirement for specific amino acid residues in the cytoplasmic domain of CD4. J
Virol 67:7238-7245.
159. Leonard, C. K., M. W. Spellman, L. Riddle, et al. 1990. Assignment of
intrachain disulfide bonds and characterization of potential glycosylation sites of
the type 1 recombinant human immunodeficiency virus envelope glycoprotein
(gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
160. Levin, J. G., J. Guo, I. Rouzina, and K. Musier-Forsyth. 2005. Nucleic acid
chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse
transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol 80:217-
286.
127
161. Li, F., R. Goila-Gaur, K. Salzwedel, et al. 2003. PA-457: a potent HIV inhibitor
that disrupts core condensation by targeting a late step in Gag processing. Proc Natl
Acad Sci U S A 100:13555-13560.
162. Li, S., J. Juarez, M. Alali, et al. 1999. Persistent CCR5 utilization and enhanced
macrophage tropism by primary blood human immunodeficiency virus type 1
isolates from advanced stages of disease and comparison to tissue-derived isolates.
J Virol 73:9741-9755.
163. Li, Y., J. C. Kappes, J. A. Conway, et al. 1991. Molecular characterization of
human immunodeficiency virus type 1 cloned directly from uncultured human brain
tissue: identification of replication-competent and -defective viral genomes. J Virol
65:3973-3985.
164. Li, Y., S. A. Migueles, B. Welcher, et al. 2007. Broad HIV-1 neutralization
mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
165. Lindwasser, O. W., R. Chaudhuri, and J. S. Bonifacino. 2007. Mechanisms of
CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency
viruses. Curr Mol Med 7:171-184.
166. Lopez-Verges, S., G. Camus, G. Blot, et al. 2006. Tail-interacting protein TIP47
is a connector between Gag and Env and is required for Env incorporation into
HIV-1 virions. Proc Natl Acad Sci U S A 103:14947-14952.
167. Laboratory, L. A. N. The Circulating Recombinant Forms.
168. Lu, Y. L., P. Spearman, and L. Ratner. 1993. Human immunodeficiency virus
type 1 viral protein R localization in infected cells and virions. J Virol 67:6542-
6550.
169. Ly, A., and L. Stamatatos. 2000. V2 loop glycosylation of the human
immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein
with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3
loop and anti-CD4 binding site antibodies. J Virol 74:6769-6776.
170. Madani, N., and D. Kabat. 1998. An endogenous inhibitor of human
immunodeficiency virus in human lymphocytes is overcome by the viral Vif
protein. J Virol 72:10251-10255.
171. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional
dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant
repressor of Rev function. Cell 58:205-214.
172. Malim, M. H., J. Hauber, S. Y. Le, J. V. Maizel, and B. R. Cullen. 1989. The
HIV-1 rev trans-activator acts through a structured target sequence to activate
nuclear export of unspliced viral mRNA. Nature 338:254-257.
173. Malim, M. H., L. S. Tiley, D. F. McCarn, et al. 1990. HIV-1 structural gene
expression requires binding of the Rev trans-activator to its RNA target sequence.
Cell 60:675-683.
174. Mangeat, B., P. Turelli, S. Liao, and D. Trono. 2004. A single amino acid
determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J.
Biol. Chem. 279:14481-14483.
128
175. Margottin, F., S. P. Bour, H. Durand, et al. 1998. A novel human WD protein, h-
beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation
pathway through an F-box motif. Mol Cell 1:565-574.
176. Mariani, R., D. Chen, B. Schrofelbauer, et al. 2003. Species-specific exclusion of
APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
177. Markovitz, D. M., M. J. Smith, J. Hilfinger, et al. 1992. Activation of the human
immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B
regulatory elements. J Virol 66:5479-5484.
178. Massiah, M. A., M. R. Starich, C. Paschall, et al. 1994. Three-dimensional
structure of the human immunodeficiency virus type 1 matrix protein. J. Mol. Biol.
244:198-223.
179. McBride, M. S., and A. T. Panganiban. 1996. The human immunodeficiency
virus type 1 encapsidation site is a multipartite RNA element composed of
functional hairpin structures. J Virol 70:2963-2973.
180. McBride, M. S., M. D. Schwartz, and A. T. Panganiban. 1997. Efficient
encapsidation of human immunodeficiency virus type 1 vectors and further
characterization of cis elements required for encapsidation. J Virol 71:4544-4554.
181. McCutchan, F. E. 2000. Understanding the genetic diversity of HIV-1. AIDS 14
Suppl 3:S31-44.
182. McDougal, J. S., P. J. Maddon, A. G. Dalgleish, et al. 1986. The T4 glycoprotein
is a cell-surface receptor for the AIDS virus. Cold Spring Harb. Symp. Quant. Biol.
51 Pt 2:703-711.
183. Mehle, A., B. Strack, P. Ancuta, et al. 2004. Vif overcomes the innate antiviral
activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome
pathway. J. Biol. Chem. 279:7792-7798.
184. Miller, M., J. Schneider, B. K. Sathyanarayana, et al. 1989. Structure of
complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A
resolution. Science 246:1149-1152.
185. Miller, M. A., M. W. Cloyd, J. Liebmann, et al. 1993. Alterations in cell
membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1
transmembrane protein. Virology 196:89-100.
186. Miller, M. A., R. F. Garry, J. M. Jaynes, and R. C. Montelaro. 1991. A
structural correlation between lentivirus transmembrane proteins and natural
cytolytic peptides. AIDS Res. Hum. Retroviruses 7:511-519.
187. Mori, K., D. J. Ringler, and R. C. Desrosiers. 1993. Restricted replication of
simian immunodeficiency virus strain 239 in macrophages is determined by env but
is not due to restricted entry. J Virol 67:2807-2814.
188. Murakami, T., and E. O. Freed. 2000. Genetic evidence for an interaction
between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the
gp41 cytoplasmic tail. J Virol 74:3548-3554.
189. Muriaux, D., J. Mirro, D. Harvin, and A. Rein. 2001. RNA is a structural
element in retrovirus particles. Proc Natl Acad Sci U S A 98:5246-5251.
129
190. Neil, S. J., S. W. Eastman, N. Jouvenet, and P. D. Bieniasz. 2006. HIV-1 Vpu
promotes release and prevents endocytosis of nascent retrovirus particles from the
plasma membrane. PLoS Pathog 2:e39.
191. Neil, S. J., T. Zang, and P. D. Bieniasz. 2008. Tetherin inhibits retrovirus release
and is antagonized by HIV-1 Vpu. Nature 451:425-430.
192. Noble, B., P. Abada, J. Nunez-Iglesias, and P. M. Cannon. 2006. Recruitment of
the adaptor protein 2 complex by the human immunodeficiency virus type 2
envelope protein is necessary for high levels of virus release. J Virol 80:2924-2932.
193. O'Doherty, U., W. J. Swiggard, and M. H. Malim. 2000. Human
immunodeficiency virus type 1 spinoculation enhances infection through virus
binding. J Virol 74:10074-10080.
194. Ohno, H., R. C. Aguilar, M. C. Fournier, et al. 1997. Interaction of endocytic
signals from the HIV-1 envelope glycoprotein complex with members of the
adaptor medium chain family. Virology 238:305-315.
195. Olsson, J., M. Poles, A. L. Spetz, et al. 2000. Human immunodeficiency virus type
1 infection is associated with significant mucosal inflammation characterized by
increased expression of CCR5, CXCR4, and beta-chemokines. J. Infect. Dis.
182:1625-1635.
196. Ono, A., S. D. Ablan, S. J. Lockett, K. Nagashima, and E. O. Freed. 2004.
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the
plasma membrane. Proc Natl Acad Sci U S A 101:14889-14894.
197. Ono, A., J. M. Orenstein, and E. O. Freed. 2000. Role of the Gag matrix domain
in targeting human immunodeficiency virus type 1 assembly. J Virol 74:2855-2866.
198. Pacyniak, E., M. L. Gomez, L. M. Gomez, et al. 2005. Identification of a region
within the cytoplasmic domain of the subtype B Vpu protein of human
immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi
complex and its absence in the Vpu protein from a subtype C HIV-1. AIDS Res.
Hum. Retroviruses 21:379-394.
199. Pelchen-Matthews, A., B. Kramer, and M. Marsh. 2003. Infectious HIV-1
assembles in late endosomes in primary macrophages. J. Cell Biol. 162:443-455.
200. Pellegrin, I., E. Legrand, D. Neau, et al. 1996. Kinetics of appearance of
neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and
relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr
Hum Retrovirol 11:438-447.
201. Peters, P. J., J. Bhattacharya, S. Hibbitts, et al. 2004. Biological analysis of
human immunodeficiency virus type 1 R5 envelopes amplified from brain and
lymph node tissues of AIDS patients with neuropathology reveals two distinct
tropism phenotypes and identifies envelopes in the brain that confer an enhanced
tropism and fusigenicity for macrophages. J Virol 78:6915-6926.
202. Peters, P. J., M. J. Duenas-Decamp, W. M. Sullivan, et al. 2008. Variation in
HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block
envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
Retrovirology 5:5.
130
203. Peters, P. J., W. M. Sullivan, M. J. Duenas-Decamp, et al. 2006. Non-
macrophage-tropic human immunodeficiency virus type 1 R5 envelopes
predominate in blood, lymph nodes, and semen: implications for transmission and
pathogenesis. J Virol 80:6324-6332.
204. Piguet, V., Y. L. Chen, A. Mangasarian, et al. 1998. Mechanism of Nef-induced
CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes.
EMBO J. 17:2472-2481.
205. Pilgrim, A. K., G. Pantaleo, O. J. Cohen, et al. 1997. Neutralizing antibody
responses to human immunodeficiency virus type 1 in primary infection and long-
term-nonprogressive infection. J. Infect. Dis. 176:924-932.
206. Pinter, A., W. J. Honnen, S. A. Tilley, et al. 1989. Oligomeric structure of gp41,
the transmembrane protein of human immunodeficiency virus type 1. J Virol
63:2674-2679.
207. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998.
Effects of CCR5 and CD4 cell surface concentrations on infections by
macrophagetropic isolates of human immunodeficiency virus type 1. J Virol
72:2855-2864.
208. Pollakis, G., S. Kang, A. Kliphuis, et al. 2001. N-linked glycosylation of the HIV
type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4
coreceptor utilization. J. Biol. Chem. 276:13433-13441.
209. Ratner, L., W. Haseltine, R. Patarca, et al. 1985. Complete nucleotide sequence
of the AIDS virus, HTLV-III. Nature 313:277-284.
210. Repik, A., K. H. Richards, and P. R. Clapham. 2007. The promise of CCR5
antagonists as new therapies for HIV-1. Curr Opin Investig Drugs 8:130-139.
211. Roben, P., J. P. Moore, M. Thali, et al. 1994. Recognition properties of a panel of
human recombinant Fab fragments to the CD4 binding site of gp120 that show
differing abilities to neutralize human immunodeficiency virus type 1. J Virol
68:4821-4828.
212. Rosen, C. A., J. G. Sodroski, and W. A. Haseltine. 1985. The location of cis-
acting regulatory sequences in the human T cell lymphotropic virus type III
(HTLV-III/LAV) long terminal repeat. Cell 41:813-823.
213. Rousso, I., M. B. Mixon, B. K. Chen, and P. S. Kim. 2000. Palmitoylation of the
HIV-1 envelope glycoprotein is critical for viral infectivity. Proc Natl Acad Sci U S
A 97:13523-13525.
214. Saad, J. S., E. Loeliger, P. Luncsford, et al. 2007. Point mutations in the HIV-1
matrix protein turn off the myristyl switch. J. Mol. Biol. 366:574-585.
215. Saad, J. S., J. Miller, J. Tai, et al. 2006. Structural basis for targeting HIV-1 Gag
proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A
103:11364-11369.
216. Sakai, H., K. Tokunaga, M. Kawamura, and A. Adachi. 1995. Function of
human immunodeficiency virus type 1 Vpu protein in various cell types. J. Gen.
Virol. 76:2717-2722.
131
217. Saphire, E. O., P. W. Parren, R. Pantophlet, et al. 2001. Crystal structure of a
neutralizing human IGG against HIV-1: a template for vaccine design. Science
293:1155-1159.
218. Sattentau, Q. J., and J. P. Moore. 1991. Conformational changes induced in the
human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J.
Exp. Med. 174:407-415.
219. Sattentau, Q. J., J. P. Moore, F. Vignaux, F. Traincard, and P. Poignard. 1993.
Conformational changes induced in the envelope glycoproteins of the human and
simian immunodeficiency viruses by soluble receptor binding. J Virol 67:7383-
7393.
220. Scarlatti, G., E. Tresoldi, A. Bjorndal, et al. 1997. In vivo evolution of HIV-1 co-
receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med.
3:1259-1265.
221. Schaal, H., M. Klein, P. Gehrmann, O. Adams, and A. Scheid. 1995.
Requirement of N-terminal amino acid residues of gp41 for human
immunodeficiency virus type 1-mediated cell fusion. J Virol 69:3308-3314.
222. Schacker, T., S. Little, E. Connick, et al. 2001. Productive infection of T cells in
lymphoid tissues during primary and early human immunodeficiency virus
infection. J. Infect. Dis. 183:555-562.
223. Schindler, M., S. Wurfl, P. Benaroch, et al. 2003. Down-modulation of mature
major histocompatibility complex class II and up-regulation of invariant chain cell
surface expression are well-conserved functions of human and simian
immunodeficiency virus nef alleles. J Virol 77:10548-10556.
224. Schmit, J. C., and B. Weber. 1997. Recent advances in antiretroviral therapy and
HIV infection monitoring. Intervirology 40:304-321.
225. Schubert, U., L. C. Anton, I. Bacik, et al. 1998. CD4 glycoprotein degradation
induced by human immunodeficiency virus type 1 Vpu protein requires the function
of proteasomes and the ubiquitin-conjugating pathway. J Virol 72:2280-2288.
226. Schubert, U., S. Bour, A. V. Ferrer-Montiel, et al. 1996. The two biological
activities of human immunodeficiency virus type 1 Vpu protein involve two
separable structural domains. J Virol 70:809-819.
227. Schubert, U., S. Bour, R. L. Willey, and K. Strebel. 1999. Regulation of virus
release by the macrophage-tropic human immunodeficiency virus type 1 AD8
isolate is redundant and can be controlled by either Vpu or Env. J Virol 73:887-896.
228. Schubert, U., K. A. Clouse, and K. Strebel. 1995. Augmentation of virus
secretion by the human immunodeficiency virus type 1 Vpu protein is cell type
independent and occurs in cultured human primary macrophages and lymphocytes.
J Virol 69:7699-7711.
229. Schubert, U., A. V. Ferrer-Montiel, M. Oblatt-Montal, et al. 1996. Identification
of an ion channel activity of the Vpu transmembrane domain and its involvement in
the regulation of virus release from HIV-1-infected cells. FEBS Lett. 398:12-18.
230. Schubert, U., P. Henklein, B. Boldyreff, et al. 1994. The human
immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein
132
kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-
alpha-helix-motif. J. Mol. Biol. 236:16-25.
231. Schwartz, D. H., R. Viscidi, O. Laeyendecker, et al. 1996. Predominance of
defective proviral sequences in an HIV + long-term non-progressor. Immunol. Lett.
51:3-6.
232. Schwartz, S., B. K. Felber, E. M. Fenyo, and G. N. Pavlakis. 1990. Env and Vpu
proteins of human immunodeficiency virus type 1 are produced from multiple
bicistronic mRNAs. J Virol 64:5448-5456.
233. Schwartz, S., B. K. Felber, and G. N. Pavlakis. 1992. Mechanism of translation
of monocistronic and multicistronic human immunodeficiency virus type 1
mRNAs. Mol. Cell. Biol. 12:207-219.
234. Sharova, N., C. Swingler, M. Sharkey, and M. Stevenson. 2005. Macrophages
archive HIV-1 virions for dissemination in trans. EMBO J. 24:2481-2489.
235. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a
human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
Nature 418:646-650.
236. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med.
9:1404-1407.
237. Simmons, G., A. McKnight, Y. Takeuchi, H. Hoshino, and P. R. Clapham.
1995. Cell-to-cell fusion, but not virus entry in macrophages by T-cell line tropic
HIV-1 strains: a V3 loop-determined restriction. Virology 209:696-700.
238. Simmons, G., J. D. Reeves, A. McKnight, et al. 1998. CXCR4 as a functional
coreceptor for human immunodeficiency virus type 1 infection of primary
macrophages. J Virol 72:8453-8457.
239. Simmons, G., D. Wilkinson, J. D. Reeves, et al. 1996. Primary, syncytium-
inducing human immunodeficiency virus type 1 isolates are dual-tropic and most
can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 70:8355-8360.
240. Smit, T. K., B. Wang, T. Ng, et al. 2001. Varied tropism of HIV-1 isolates derived
from different regions of adult brain cortex discriminate between patients with and
without AIDS dementia complex (ADC): evidence for neurotropic HIV variants.
Virology 279:509-526.
241. Soda, Y., N. Shimizu, A. Jinno, et al. 1999. Establishment of a new system for
determination of coreceptor usages of HIV based on the human glioma NP-2 cell
line. Biochem. Biophys. Res. Commun. 258:313-321.
242. Speck, R. F., K. Wehrly, E. J. Platt, et al. 1997. Selective employment of
chemokine receptors as human immunodeficiency virus type 1 coreceptors
determined by individual amino acids within the envelope V3 loop. J Virol
71:7136-7139.
243. Starcich, B. R., B. H. Hahn, G. M. Shaw, et al. 1986. Identification and
characterization of conserved and variable regions in the envelope gene of HTLV-
III/LAV, the retrovirus of AIDS. Cell 45:637-648.
133
244. Goff, S. R. 2007. Retroviridae: The Retroviruses and Their Replication, p. 1999-
2069. In David M. Knipe, P. M. H. (ed.), Fields Virology, Lippincott Williams &
Wilkins, Philadelphia.
245. Stephens, E. B., C. McCormick, E. Pacyniak, et al. 2002. Deletion of the vpu
sequences prior to the env in a simian-human immunodeficiency virus results in
enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques.
Virology 293:252-261.
246. Sterjovski, J., M. J. Churchill, A. Ellett, et al. 2007. Asn 362 in gp120
contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope
glycoprotein variants from patients with AIDS. Retrovirology 4:89.
247. Strebel, K., T. Klimkait, and M. A. Martin. 1988. A novel gene of HIV-1, vpu,
and its 16-kilodalton product. Science 241:1221-1223.
248. Sullivan, N., Y. Sun, Q. Sattentau, et al. 1998. CD4-Induced conformational
changes in the human immunodeficiency virus type 1 gp120 glycoprotein:
consequences for virus entry and neutralization. J Virol 72:4694-4703.
249. Swigut, T., N. Shohdy, and J. Skowronski. 2001. Mechanism for down-regulation
of CD28 by Nef. EMBO J. 20:1593-1604.
250. Swingler, S., B. Brichacek, J. M. Jacque, et al. 2003. HIV-1 Nef intersects the
macrophage CD40L signalling pathway to promote resting-cell infection. Nature
424:213-219.
251. Takahashi, K., S. L. Wesselingh, D. E. Griffin, et al. 1996. Localization of HIV-1
in human brain using polymerase chain reaction/in situ hybridization and
immunocytochemistry. Ann. Neurol. 39:705-711.
252. Teeraputon, S., S. Louisirirojchanakul, and P. Auewarakul. 2005. N-linked
glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing
antibodies. Viral Immunol. 18:343-353.
253. Tersmette, M., J. M. Lange, R. E. de Goede, et al. 1989. Association between
biological properties of human immunodeficiency virus variants and risk for AIDS
and AIDS mortality. Lancet 1:983-985.
254. Theodore, T. S., G. Englund, A. Buckler-White, et al. 1996. Construction and
characterization of a stable full-length macrophage-tropic HIV type 1 molecular
clone that directs the production of high titers of progeny virions. AIDS Res. Hum.
Retroviruses 12:191-194.
255. Thomas, E. R., R. L. Dunfee, J. Stanton, et al. 2007. High frequency of defective
vpu compared with tat and rev genes in brain from patients with HIV type 1-
associated dementia. AIDS Res. Hum. Retroviruses 23:575-580.
256. Thomas, E. R., R. L. Dunfee, J. Stanton, et al. 2007. Macrophage entry mediated
by HIV Envs from brain and lymphoid tissues is determined by the capacity to use
low CD4 levels and overall efficiency of fusion. Virology 360:105-119.
257. Tuttle, D. L., C. B. Anders, M. J. Aquino-De Jesus, et al. 2002. Increased
replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived
macrophages is linked to advanced disease in infected children. AIDS Res. Hum.
Retroviruses 18:353-362.
258. UNAIDS. UNAIDS Fact Sheet 11 07.
134
259. Valsamakis, A., S. Zeichner, S. Carswell, and J. C. Alwine. 1991. The human
immunodeficiency virus type 1 polyadenylylation signal: a 3' long terminal repeat
element upstream of the AAUAAA necessary for efficient polyadenylylation. Proc
Natl Acad Sci U S A 88:2108-2112.
260. Van Damme, N., D. Goff, C. Katsura, et al. 2008. The interferon-induced protein
BST-2 restricts HIV-1 release and is downregulated from the cell surface by the
viral Vpu protein. Cell Host Microbe 3:245-252.
261. Van Heuverswyn, F., Y. Li, C. Neel, et al. 2006. Human immunodeficiency
viruses: SIV infection in wild gorillas. Nature 444:164.
262. Varthakavi, V., E. Heimann-Nichols, R. M. Smith, et al. 2008. Identification of
calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release
overcome by Vpu. Nat. Med. 14:641-647.
263. Varthakavi, V., R. M. Smith, S. P. Bour, K. Strebel, and P. Spearman. 2003.
Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle
production. Proc Natl Acad Sci U S A 100:15154-15159.
264. Varthakavi, V., R. M. Smith, K. L. Martin, et al. 2006. The pericentriolar
recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1
particle release. Traffic 7:298-307.
265. Veazey, R. S., M. DeMaria, L. V. Chalifoux, et al. 1998. Gastrointestinal tract as
a major site of CD4+ T cell depletion and viral replication in SIV infection. Science
280:427-431.
266. Verani, A., G. Gras, and G. Pancino. 2005. Macrophages and HIV-1: dangerous
liaisons. Mol. Immunol. 42:195-212.
267. Veronese, F. D., A. L. DeVico, T. D. Copeland, et al. 1985. Characterization of
gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.
Science 229:1402-1405.
268. VerPlank, L., F. Bouamr, T. J. LaGrassa, et al. 2001. Tsg101, a homologue of
ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag).
Proc Natl Acad Sci U S A 98:7724-7729.
269. Vincent, M. J., N. U. Raja, and M. A. Jabbar. 1993. Human immunodeficiency
virus type 1 Vpu protein induces degradation of chimeric envelope glycoproteins
bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic
domain in Vpu-induced degradation in the endoplasmic reticulum. J Virol 67:5538-
5549.
270. Vogt, V. M., R. Eisenman, and H. Diggelmann. 1975. Generation of avian
myeloblastosis virus structural proteins by proteolytic cleavage of a precursor
polypeptide. J. Mol. Biol. 96:471-493.
271. Wain-Hobson, S., P. Sonigo, O. Danos, S. Cole, and M. Alizon. 1985. Nucleotide
sequence of the AIDS virus, LAV. Cell 40:9-17.
272. Wei, X., J. M. Decker, H. Liu, et al. 2002. Emergence of resistant human
immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20)
monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
273. Wei, X., J. M. Decker, S. Wang, et al. 2003. Antibody neutralization and escape
by HIV-1. Nature 422:307-312.
135
274. Weiss, C. D., J. A. Levy, and J. M. White. 1990. Oligomeric organization of
gp120 on infectious human immunodeficiency virus type 1 particles. J Virol
64:5674-5677.
275. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley.
1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430.
276. Weissenhorn, W., S. A. Wharton, L. J. Calder, et al. 1996. The ectodomain of
HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the
absence of gp120 and the N-terminal fusion peptide. EMBO J. 15:1507-1514.
277. Westervelt, P., D. B. Trowbridge, L. G. Epstein, et al. 1992. Macrophage tropism
determinants of human immunodeficiency virus type 1 in vivo. J Virol 66:2577-
2582.
278. Willey, R. L., F. Maldarelli, M. A. Martin, and K. Strebel. 1992. Human
immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J
Virol 66:7193-7200.
279. Willey, R. L., F. Maldarelli, M. A. Martin, and K. Strebel. 1992. Human
immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular
gp160-CD4 complexes. J Virol 66:226-234.
280. Willey, S., P. J. Peters, W. M. Sullivan, et al. 2005. Inhibition of CCR5-mediated
infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule
inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Antiviral Res. 68:96-108.
281. Williams, K. C., and W. F. Hickey. 2002. Central nervous system damage,
monocytes and macrophages, and neurological disorders in AIDS. Annu. Rev.
Neurosci. 25:537-562.
282. Worthylake, D. K., H. Wang, S. Yoo, W. I. Sundquist, and C. P. Hill. 1999.
Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution.
Acta Crystallogr D Biol Crystallogr 55:85-92.
283. Wyatt, R., J. Moore, M. Accola, et al. 1995. Involvement of the V1/V2 variable
loop structure in the exposure of human immunodeficiency virus type 1 gp120
epitopes induced by receptor binding. J Virol 69:5723-5733.
284. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens,
antigens, and immunogens. Science 280:1884-1888.
285. Wyatt, R., N. Sullivan, M. Thali, et al. 1993. Functional and immunologic
characterization of human immunodeficiency virus type 1 envelope glycoproteins
containing deletions of the major variable regions. J Virol 67:4557-4565.
286. Wyss, S., C. Berlioz-Torrent, M. Boge, et al. 2001. The highly conserved C-
terminal dileucine motif in the cytosolic domain of the human immunodeficiency
virus type 1 envelope glycoprotein is critical for its association with the AP-1
clathrin adaptor [correction of adapter]. J Virol 75:2982-2992.
287. Yang, C., C. P. Spies, and R. W. Compans. 1995. The human and simian
immunodeficiency virus envelope glycoprotein transmembrane subunits are
palmitoylated. Proc Natl Acad Sci U S A 92:9871-9875.
288. Yao, X. J., J. Friborg, F. Checroune, et al. 1995. Degradation of CD4 induced by
human immunodeficiency virus type 1 Vpu protein: a predicted alpha-helix
136
structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity.
Virology 209:615-623.
289. Yu, X., Y. Yu, B. Liu, et al. 2003. Induction of APOBEC3G ubiquitination and
degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
290. Yuan, X., Z. Matsuda, M. Matsuda, M. Essex, and T. H. Lee. 1990. Human
immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res.
Hum. Retroviruses 6:1265-1271.
291. Zhang, H., B. Yang, R. J. Pomerantz, et al. 2003. The cytidine deaminase
CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-
98.
292. Zhang, Z., T. Schuler, M. Zupancic, et al. 1999. Sexual transmission and
propagation of SIV and HIV in resting and activated CD4+ T cells. Science
286:1353-1357.
293. Zhou, J., C. H. Chen, and C. Aiken. 2006. Human immunodeficiency virus type 1
resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-
betulinic acid is conferred by a variety of single amino acid substitutions at the CA-
SP1 cleavage site in Gag. J Virol 80:12095-12101.
294. Zhou, Q., D. Chen, E. Pierstorff, and K. Luo. 1998. Transcription elongation
factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages.
EMBO J. 17:3681-3691.
295. Zhu, P., J. Liu, J. J. Bess, et al. 2006. Distribution and three-dimensional structure
of AIDS virus envelope spikes. Nature 441:847-852.
